{"id":"abemaciclib","rwe":[],"_fda":{"id":"01706851-8b56-40b8-9e22-e454b3e24f95","set_id":"be4bc0de-0fdc-4d46-8d25-be43c79e6a06","openfda":{"nui":["N0000175605","N0000175082"],"unii":["60UAB198HK"],"route":["ORAL"],"rxcui":["1946830","1946836","1946838","1946840","1946842","1946844","1946846","1946848"],"spl_id":["01706851-8b56-40b8-9e22-e454b3e24f95"],"brand_name":["Verzenio"],"spl_set_id":["be4bc0de-0fdc-4d46-8d25-be43c79e6a06"],"package_ndc":["0002-4483-54","0002-4483-62","0002-4815-54","0002-4815-62","0002-5337-54","0002-5337-63","0002-5337-62","0002-6216-54"],"product_ndc":["0002-4483","0002-4815","0002-5337","0002-6216"],"generic_name":["ABEMACICLIB"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["ABEMACICLIB"],"pharm_class_epc":["Kinase Inhibitor [EPC]"],"pharm_class_moa":["Kinase Inhibitors [MoA]"],"manufacturer_name":["Eli Lilly and Company"],"application_number":["NDA208716"],"is_original_packager":[true]},"version":"27","pregnancy":["8.1 Pregnancy Risk Summary Based on findings in animals and its mechanism of action, VERZENIO can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus. In animal reproduction studies, administration of abemaciclib during organogenesis was teratogenic and caused decreased fetal weight at maternal exposures that were similar to human clinical exposure based on AUC at the maximum recommended human dose ( see Data). Advise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies. Data Animal Data In an embryo-fetal development study, pregnant rats received oral doses of abemaciclib up to 15 mg/kg/day during the period of organogenesis. Doses ≥4 mg/kg/day caused decreased fetal body weights and increased incidence of cardiovascular and skeletal malformations and variations. These findings included absent innominate artery and aortic arch, malpositioned subclavian artery, unossified sternebra, bipartite ossification of thoracic centrum, and rudimentary or nodulated ribs. At 4 mg/kg/day in rats, the maternal systemic exposures were approximately equal to the human exposure (AUC) at the recommended dose."],"description":["11 DESCRIPTION Abemaciclib is a kinase inhibitor for oral administration. It is a white to yellow powder with the empirical formula C 27 H 32 F 2 N 8 and a molecular weight 506.59. The chemical name for abemaciclib is 2-Pyrimidinamine, N -[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1 H -benzimidazol-6-yl]-. Abemaciclib has the following structure: VERZENIO (abemaciclib) tablets are provided as immediate-release oval white, beige, or yellow tablets. Inactive ingredients are as follows: Excipients—microcrystalline cellulose 102, microcrystalline cellulose 101, lactose monohydrate, croscarmellose sodium, sodium stearyl fumarate, silicon dioxide. Color mixture ingredients—polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide yellow, and iron oxide red. Abemaciclib Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied VERZENIO 50 mg tablets are oval beige tablet with “Lilly” debossed on one side and “50” on the other side. VERZENIO 100 mg tablet are oval white to practically white tablet with “Lilly” debossed on one side and “100” on the other side. VERZENIO 150 mg tablets are oval yellow tablet with “Lilly” debossed on one side and “150” on the other side. VERZENIO 200 mg tablets are oval beige tablet with “Lilly” debossed on one side and “200” on the other side. VERZENIO tablets are supplied in 7-day dose pack configurations as follows: 200 mg dose pack (14 tablets) – each blister pack contains 14 tablets (200 mg per tablet) (200 mg twice daily) NDC 0002-6216-54 150 mg dose pack (14 tablets) – each blister pack contains 14 tablets (150 mg per tablet) (150 mg twice daily) NDC 0002-5337-54 100 mg dose pack (14 tablets) – each blister pack contains 14 tablets (100 mg per tablet) (100 mg twice daily) NDC 0002-4815-54 50 mg dose pack (14 tablets) – each blister pack contains 14 tablets (50 mg per tablet) (50 mg twice daily) NDC 0002-4483-54 Storage and Handling Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).","How Supplied VERZENIO 50 mg tablets are oval beige tablet with “Lilly” debossed on one side and “50” on the other side. VERZENIO 100 mg tablet are oval white to practically white tablet with “Lilly” debossed on one side and “100” on the other side. VERZENIO 150 mg tablets are oval yellow tablet with “Lilly” debossed on one side and “150” on the other side. VERZENIO 200 mg tablets are oval beige tablet with “Lilly” debossed on one side and “200” on the other side. VERZENIO tablets are supplied in 7-day dose pack configurations as follows: 200 mg dose pack (14 tablets) – each blister pack contains 14 tablets (200 mg per tablet) (200 mg twice daily) NDC 0002-6216-54 150 mg dose pack (14 tablets) – each blister pack contains 14 tablets (150 mg per tablet) (150 mg twice daily) NDC 0002-5337-54 100 mg dose pack (14 tablets) – each blister pack contains 14 tablets (100 mg per tablet) (100 mg twice daily) NDC 0002-4815-54 50 mg dose pack (14 tablets) – each blister pack contains 14 tablets (50 mg per tablet) (50 mg twice daily) NDC 0002-4483-54"],"geriatric_use":["8.5 Geriatric Use Of the 2791 VERZENIO-treated patients in monarchE, 15% were 65 years of age or older and 2.7% were 75 years of age or older. Of the 900 patients who received VERZENIO in MONARCH 1, MONARCH 2, and MONARCH 3, 38% were 65 years of age or older and 10% were 75 years of age or older. The most common adverse reactions (≥5%) Grade 3 or 4 in patients ≥65 years of age across MONARCH 1, 2, and 3 were: neutropenia, diarrhea, fatigue, nausea, dehydration, leukopenia, anemia, infections, and ALT increased. No overall differences in safety or effectiveness of VERZENIO were observed between these patients and younger patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of VERZENIO have not been established in pediatric patients. The safety and effectiveness of VERZENIO in combination with chemotherapy was assessed but not established in an open label, dose-finding trial (NCT04238819) in 43 pediatric patients aged 1 to < 17 years with relapsed/refractory solid tumors. No new safety signals were observed in pediatric patients in this study. Abemaciclib exposure in pediatric patients was within the range of the values previously observed in adults given a similar dose per body surface area."],"effective_time":"20250825","clinical_studies":["14 CLINICAL STUDIES 14.1 Early Breast Cancer VERZENIO in Combination with Standard Endocrine Therapy (monarchE) Patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence monarchE (NCT03155997) was a randomized (1:1), open-label, two cohort, multicenter study in adult women and men with HR-positive, HER2-negative, node-positive, resected, early breast cancer with clinical and pathological features consistent with a high risk of disease recurrence. To be enrolled, patients had to have HR-positive HER2-negative early breast cancer with tumor involvement in at least 1 axillary lymph node (pALN) and to be enrolled in cohort 1 had to have either: ≥4 pALN or 1-3 pALN and at least one of: – tumor grade 3 or – tumor size ≥50 mm Patients enrolled in cohort 2 could not have met the eligibility criteria for cohort 1. To be enrolled in cohort 2, patients had to have 1-3 pALN and Ki-67 score ≥20%. Breast tumor samples were tested at central sites using the Ki-67 IHC MIB-1 pharmDx (Dako Omnis) assay to establish if the Ki-67 score was ≥20%. Patients were randomized to receive 2 years of VERZENIO plus physician's choice of standard endocrine therapy or standard endocrine therapy alone. Randomization to treatment was stratified by prior treatment (neoadjuvant chemotherapy versus adjuvant chemotherapy versus no chemotherapy); menopausal status (premenopausal versus postmenopausal); and region (North America/Europe versus Asia versus other). Men were stratified as postmenopausal. After the end of the study treatment period, standard adjuvant endocrine therapy was continued for a duration of at least 5 years if deemed medically appropriate. The major efficacy outcome measure was invasive disease–free survival (IDFS). IDFS was defined as the time from randomization to the first occurrence of: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, or death attributable to any cause. Overall survival (OS) was an additional outcome measure. A statistically significant difference in IDFS was observed in the intent-to-treat (ITT) population which was primarily attributed to the patients treated in cohort 1. While the OS data in cohort 2 remains immature, more deaths were observed among those receiving VERZENIO plus standard endocrine therapy compared to those receiving standard endocrine therapy alone (10/253 vs. 5/264). Of 5637 patients randomized, 5120 (91%) were randomized in cohort 1. Patient median age was 51 years (range, 22-89 years), 99% were women, 70% were White, 24% were Asian, 1.7% were Black or African American, 2.1% were American Indian or Alaska Native, and 0.1% were Native Hawaiian or Other Pacific Islander. Forty-three percent of patients were premenopausal. Most patients received prior chemotherapy (37% neoadjuvant, 59% adjuvant) and prior radiotherapy (96%). Sixty-five percent of the patients had 4 or more positive lymph nodes with 22% having ≥10 positive lymph nodes, 41% had Grade 3 tumor, and 24% had pathological tumor size ≥50 mm. The majority of patients (99%) had estrogen receptor positive disease and 87% had progesterone receptor positive disease. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%). Efficacy results for cohort 1 are summarized in Table 16 and Figure 1 . At the time of OS interim analysis 2, OS was immature and a total of 315 (6%) of patients had died in cohort 1. Table 16: Efficacy Results in monarchE in Cohort 1 Abbreviation: CI = confidence interval. VERZENIO Plus Tamoxifen or an Aromatase Inhibitor N=2555 Tamoxifen or an Aromatase Inhibitor N=2565 Invasive Disease–Free Survival (IDFS) Number of patients with an event, n (%) 317 (12) 474 (18) Hazard ratio (95% CI) 0.65 (0.57, 0.75) IDFS at 48 months, % (95% CI) 85.5 (83.8, 87.0) 78.6 (76.7, 80.4) Figure 1: Kaplan-Meier Curves of Invasive Disease–Free Survival VERZENIO plus Tamoxifen or an Aromatase Inhibitor versus Tamoxifen or an Aromatase Inhibitor in Cohort 1 (monarchE) Figure 1 14.2 Advanced or Metastatic Breast Cancer VERZENIO in Combination with an Aromatase Inhibitor (Anastrozole or Letrozole) (MONARCH 3) Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer with no prior systemic therapy in this disease setting MONARCH 3 (NCT02246621) was a randomized (2:1), double-blinded, placebo-controlled, multicenter study in postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with a nonsteroidal aromatase inhibitor as initial endocrine-based therapy, including patients not previously treated with systemic therapy for breast cancer. Randomization was stratified by disease site (visceral, bone only, or other) and by prior (neo)adjuvant endocrine therapy (aromatase inhibitor versus other versus no prior endocrine therapy). A total of 493 patients were randomized to receive 150 mg VERZENIO or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20% of patients). Patient median age was 63 years (range, 32-88 years) and the majority were White (58%) or Asian (30%). A total of 51% had received prior systemic therapy and 39% of patients had received chemotherapy, 53% had visceral disease, and 22% had bone-only disease. Efficacy results are summarized in Table 17 and Figure 2 . PFS was evaluated according to RECIST version 1.1 and PFS assessment based on a blinded independent radiologic review was consistent with the investigator assessment. Consistent PFS results were observed across patient stratification subgroups of disease site and prior (neo)adjuvant endocrine therapy. Table 17: Efficacy Results in MONARCH 3 (Investigator Assessment, Intent-to-Treat Population) Abbreviations: CI = confidence interval; OS = overall survival; NR = not reached; NS = not statistically significant. a Complete response + partial response. b Based upon confirmed responses. VERZENIO plus Anastrozole or Letrozole Placebo plus Anastrozole or Letrozole Progression-Free Survival N=328 N=165 Number of patients with an event, n (%) 138 (42) 108 (65) Median in months (95% CI) 28.2 (23.5, NR) 14.8 (11.2, 19.2) Hazard ratio (95% CI) 0.54 (0.42, 0.70) p-value <0.0001 Overall Survival N=328 N=165 Number of patients with an event, n (%) 198 (60) 116 (70) Median in months (95% CI) 66.8 (59.2, 74.8) 53.7 (44.7, 59.3) Hazard ratio (95% CI) 0.80 (0.64, 1.02) p-value NS Objective Response for Patients with Measurable Disease a N=267 N=132 Objective response rate n (%) a,b 148 (55) 53 (40) 95% CI 49, 61 32, 49 Figure 2: Kaplan-Meier Curves of Progression-Free Survival: VERZENIO plus Anastrozole or Letrozole versus Placebo plus Anastrozole or Letrozole in Intent-to-Treat Population (MONARCH 3) Figure 2 VERZENIO in Combination with Fulvestrant (MONARCH 2) Patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression on or after prior adjuvant or metastatic endocrine therapy MONARCH 2 (NCT02107703) was a randomized, placebo-controlled, multicenter study in women with HR-positive, HER2-negative metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy who had not received chemotherapy in the metastatic setting. Randomization was stratified by disease site (visceral, bone only, or other) and by sensitivity to prior endocrine therapy (primary or secondary resistance). Primary endocrine therapy resistance was defined as relapse while on the first 2 years of adjuvant endocrine therapy or progressive disease within the first 6 months of first line endocrine therapy for metastatic breast cancer. A total of 669 patients were randomized to receive VERZENIO or placebo orally twice daily plus intramuscular injection of 500 mg fulvestrant on days 1 and 15 of cycle 1 and then on day 1 of cycle 2 and beyond (28-day cycles). Pre/perimenopausal women were enrolled in the study and received the gonadotropin-releasing hormone agonist goserelin for at least 4 weeks prior to and for the duration of MONARCH 2. Patients remained on continuous treatment until development of progressive disease or unmanageable toxicity. Patient median age was 60 years (range, 32-91 years), and 37% of patients were older than 65. The majority were White (56%), and 99% of patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Twenty percent (20%) of patients had de novo metastatic disease, 27% had bone-only disease, and 56% had visceral disease. Twenty-five percent (25%) of patients had primary endocrine therapy resistance. Seventeen percent (17%) of patients were pre- or perimenopausal. The efficacy results from the MONARCH 2 study are summarized in Table 18 , Figure 3 , and Figure 4 . PFS assessment based on a blinded independent radiologic review was consistent with the investigator assessment. Consistent results were observed across patient stratification subgroups of disease site and endocrine therapy resistance for PFS and OS. Table 18: Efficacy Results in MONARCH 2 (Intent-to-Treat Population) Abbreviation: CI = confidence interval, OS = overall survival. a Stratified by disease site (visceral metastases vs. bone-only metastases vs. other) and endocrine therapy resistance (primary resistance vs. secondary resistance) b Data from a pre-specified interim analysis (77% of the number of events needed for the planned final analysis) with the p-value compared with the allocated alpha of 0.021. c Complete response + partial response. VERZENIO plus Fulvestrant Placebo plus Fulvestrant Progression-Free Survival (Investigator Assessment) N=446 N=223 Number of patients with an event n (%) 222 (50) 157 (70) Median in months (95% CI) 16.4 (14.4, 19.3) 9.3 (7.4, 12.7) Hazard ratio (95% CI) a 0.55 (0.45, 0.68) p-value a p<.0001 Overall Survival b Number of deaths n (%) 211 (47) 127 (57) Median OS in months (95% CI) 46.7 (39.2, 52.2) 37.3 (34.4, 43.2) Hazard ratio (95% CI) a 0.76 (0.61, 0.95) p-value a p=.0137 Objective Response for Patients with Measurable Disease N=318 N=164 Objective response rate n (%) c 153 (48) 35 (21) 95% CI 43, 54 15, 28 Figure 3: Kaplan-Meier Curves of Progression-Free Survival: VERZENIO plus Fulvestrant versus Placebo plus Fulvestrant (MONARCH 2) Figure 4: Kaplan-Meier Curves of Overall Survival: VERZENIO plus Fulvestrant versus Placebo plus Fulvestrant (MONARCH 2) Figure 3 Figure 4 VERZENIO Administered as a Monotherapy in Metastatic Breast Cancer (MONARCH 1) Patients with HR-positive, HER2-negative breast cancer who received prior endocrine therapy and 1-2 chemotherapy regimens in the metastatic setting MONARCH 1 (NCT02102490) was a single-arm, open-label, multicenter study in women with measurable HR-positive, HER2-negative metastatic breast cancer whose disease progressed during or after endocrine therapy, had received a taxane in any setting, and who received 1 or 2 prior chemotherapy regimens in the metastatic setting. A total of 132 patients received 200 mg VERZENIO orally twice daily on a continuous schedule until development of progressive disease or unmanageable toxicity. Patient median age was 58 years (range, 36-89 years), and the majority of patients were White (85%). Patients had an Eastern Cooperative Oncology Group performance status of 0 (55% of patients) or 1 (45%). The median duration of metastatic disease was 27.6 months. Ninety percent (90%) of patients had visceral metastases, and 51% of patients had 3 or more sites of metastatic disease. Fifty-one percent (51%) of patients had had one line of chemotherapy in the metastatic setting. Sixty-nine percent (69%) of patients had received a taxane-based regimen in the metastatic setting and 55% had received capecitabine in the metastatic setting. Table 19 provides the efficacy results from MONARCH 1. Table 19: Efficacy Results in MONARCH 1 (Intent-to-Treat Population) Abbreviations: CI = confidence interval, NR = not reached. a All responses were partial responses. b Based upon confirmed responses. VERZENIO 200 mg N=132 Investigator Assessed Independent Review Objective Response Rate a,b , n (%) 26 (20) 23 (17) 95% CI 13, 28 11, 25 Median Duration of Response in months 8.6 7.2 95% CI 5.8, 10.2 5.6, NR"],"pharmacodynamics":["12.2 Pharmacodynamics Cardiac Electrophysiology Based on evaluation of the QTc interval in patients and in a healthy volunteer study, abemaciclib did not cause large mean increases (i.e., 20 ms) in the QTc interval."],"pharmacokinetics":["12.3 Pharmacokinetics The pharmacokinetics of abemaciclib were characterized in patients with solid tumors, including breast cancer, and in healthy subjects. Following single and repeated twice daily dosing of 50 mg (0.3 times the approved recommended 150 mg dosage) to 200 mg of abemaciclib, the increase in plasma exposure (AUC) and C max was approximately dose proportional. Steady state was achieved within 5 days following repeated twice daily dosing, and the estimated geometric mean accumulation ratio was 2.3 (50% CV) and 3.2 (59% CV) based on C max and AUC, respectively. Absorption The absolute bioavailability of abemaciclib after a single oral dose of 200 mg is 45% (19% CV). The median T max of abemaciclib is 8.0 hours (range: 4.1-24.0 hours). Effect of Food A high-fat, high-calorie meal (approximately 800 to 1000 calories with 150 calories from protein, 250 calories from carbohydrate, and 500 to 600 calories from fat) administered to healthy subjects increased the AUC of abemaciclib plus its active metabolites by 9% and increased C max by 26%. Distribution In vitro, abemaciclib was bound to human plasma proteins, serum albumin, and alpha-1-acid glycoprotein in a concentration independent manner from 152 ng/mL to 5066 ng/mL. In a clinical study, the mean (standard deviation, SD) bound fraction was 96.3% (1.1) for abemaciclib, 93.4% (1.3) for M2, 96.8% (0.8) for M18, and 97.8% (0.6) for M20. The geometric mean systemic volume of distribution is approximately 690.3 L (49% CV). In patients with advanced cancer, including breast cancer, concentrations of abemaciclib and its active metabolites M2 and M20 in cerebrospinal fluid are comparable to unbound plasma concentrations. Elimination The geometric mean hepatic clearance (CL) of abemaciclib in patients was 26.0 L/h (51% CV), and the mean plasma elimination half-life for abemaciclib in patients was 18.3 hours (72% CV). Metabolism Hepatic metabolism is the main route of clearance for abemaciclib. Abemaciclib is metabolized to several metabolites primarily by cytochrome P450 (CYP) 3A4, with formation of N-desethylabemaciclib (M2) representing the major metabolism pathway. Additional metabolites include hydroxyabemaciclib (M20), hydroxy-N-desethylabemaciclib (M18), and an oxidative metabolite (M1). M2, M18, and M20 are equipotent to abemaciclib and their AUCs accounted for 25%, 13%, and 26% of the total circulating analytes in plasma, respectively. Excretion After a single 150 mg oral dose of radiolabeled abemaciclib, approximately 81% of the dose was recovered in feces and approximately 3% recovered in urine. The majority of the dose eliminated in feces was metabolites. Specific Populations Age, Gender, and Body Weight Based on a population pharmacokinetic analysis in patients with cancer, age (range 24-91 years), gender (134 males and 856 females), and body weight (range 36-175 kg) had no effect on the exposure of abemaciclib. Patients with Renal Impairment In a population pharmacokinetic analysis of 990 individuals, in which 381 individuals had mild renal impairment (60 mL/min ≤ CLcr <90 mL/min) and 126 individuals had moderate renal impairment (30 mL/min ≤ CLcr <60 mL/min), mild and moderate renal impairment had no effect on the exposure of abemaciclib [see Use in Specific Populations ( 8.6 )] . The effect of severe renal impairment (CLcr <30 mL/min) on pharmacokinetics of abemaciclib is unknown. Patients with Hepatic Impairment Following a single 200 mg oral dose of abemaciclib, the relative potency adjusted unbound AUC 0-INF of abemaciclib plus its active metabolites (M2, M18, M20) in plasma increased 1.2-fold in subjects with mild hepatic impairment (Child-Pugh A, n=9), 1.1-fold in subjects with moderate hepatic impairment (Child-Pugh B, n=10), and 2.4-fold in subjects with severe hepatic impairment (Child-Pugh C, n=6) relative to subjects with normal hepatic function (n=10) [see Use in Specific Populations ( 8.7 )] . In subjects with severe hepatic impairment, the mean plasma elimination half-life of abemaciclib increased to 55 hours compared to 24 hours in subjects with normal hepatic function. Drug Interaction Studies Effects of Other Drugs on Abemaciclib Strong CYP3A Inhibitors: Ketoconazole (a strong CYP3A inhibitor) is predicted to increase the AUC of abemaciclib by up to 16-fold. Coadministration of 500 mg twice daily doses of clarithromycin (a strong CYP3A inhibitor) with a single 50 mg dose of VERZENIO (0.3 times the approved recommended 150 mg dosage) increased the relative potency adjusted unbound AUC 0-INF of abemaciclib plus its active metabolites (M2, M18, and M20) by 2.5-fold relative to abemaciclib alone in cancer patients. Moderate CYP3A Inhibitors: Verapamil and diltiazem (moderate CYP3A inhibitors) are predicted to increase the relative potency adjusted unbound AUC of abemaciclib plus its active metabolites (M2, M18, and M20) by approximately 1.6-fold and 2.4-fold, respectively. Strong CYP3A Inducers: Coadministration of 600 mg daily doses of rifampin (a strong CYP3A inducer) with a single 200 mg dose of VERZENIO decreased the relative potency adjusted unbound AUC 0-INF of abemaciclib plus its active metabolites (M2, M18, and M20) by approximately 70% in healthy subjects. Moderate CYP3A Inducers: Efavirenz, bosentan, and modafinil (moderate CYP3A inducers) are predicted to decrease the relative potency adjusted unbound AUC of abemaciclib plus its active metabolites (M2, M18, and M20) by 53%, 41%, and 29%, respectively. Loperamide: Co-administration of a single 8 mg dose of loperamide with a single 400 mg dose of abemaciclib in healthy subjects increased the relative potency adjusted unbound AUC 0-INF of abemaciclib plus its active metabolites (M2 and M20) by 12%, which is not considered clinically relevant. Endocrine Therapies: In clinical studies in patients with breast cancer, there was no clinically relevant effect of fulvestrant, anastrozole, letrozole, exemestane, or tamoxifen on abemaciclib pharmacokinetics. Effects of Abemaciclib on Other Drugs Loperamide: In a clinical drug interaction study in healthy subjects, coadministration of a single 8 mg dose of loperamide with a single 400 mg abemaciclib (2.7 times the approved recommended 150 mg dosage) increased loperamide AUC 0-INF by 9% and C max by 35% relative to loperamide alone. These increases in loperamide exposure are not considered clinically relevant. Metformin: In a clinical drug interaction study in healthy subjects, coadministration of a single 1000 mg dose of metformin, a clinically relevant substrate of renal OCT2, MATE1, and MATE2-K transporters, with a single 400 mg dose of abemaciclib (2.7 times the approved recommended 150 mg dosage) increased metformin AUC 0-INF by 37% and C max by 22% relative to metformin alone. Abemaciclib reduced the renal clearance and renal secretion of metformin by 45% and 62%, respectively, relative to metformin alone, without any effect on glomerular filtration rate (GFR) as measured by iohexol clearance and serum cystatin C. Endocrine Therapies: In clinical studies in patients with breast cancer, there was no clinically relevant effect of abemaciclib on the pharmacokinetics of fulvestrant, anastrozole, letrozole, exemestane, or tamoxifen. CYP Metabolic Pathways: In a clinical drug interaction study in patients with cancer, multiple doses of abemaciclib (200 mg twice daily for 7 days) did not result in clinically meaningful changes in the pharmacokinetics of CYP1A2, CYP2C9, CYP2D6 and CYP3A4 substrates. Abemaciclib is a substrate of CYP3A4, and time-dependent changes in pharmacokinetics of abemaciclib as a result of autoinhibition of its metabolism were not observed. In Vitro Studies Transporter Systems: Abemaciclib and its major active metabolites inhibit the renal transporters OCT2, MATE1, and MATE2-K at concentrations achievable at the approved recommended dosage. The observed serum creatinine increase in clinical studies with abemaciclib is likely due to inhibition of tubular secretion of creatinine via OCT2, MATE1, and MATE2-K [see Adverse Effects ( 6.1 )] . Abemaciclib and its major metabolites at clinically relevant concentrations do not inhibit the hepatic uptake transporters OCT1, OATP1B1, and OATP1B3 or the renal uptake transporters OAT1 and OAT3. Abemaciclib is a substrate of P-gp and BCRP. Abemaciclib and its major active metabolites, M2 and M20, are not substrates of hepatic uptake transporters OCT1, organic anion transporting polypeptide 1B1 (OATP1B1), or OATP1B3. Abemaciclib inhibits P-gp and BCRP. The clinical consequences of this finding on sensitive P-gp and BCRP substrates are unknown. P-gp and BCRP Inhibitors: In vitro, abemaciclib is a substrate of P-gp and BCRP. The effect of P-gp or BCRP inhibitors on the pharmacokinetics of abemaciclib has not been studied."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: Diarrhea [see Warnings and Precautions ( 5.1 )] . Neutropenia [see Warnings and Precautions ( 5.2 )] . Interstitial Lung Disease (ILD) or Pneumonitis [see Warnings and Precautions ( 5.3 )] . Hepatotoxicity [see Warnings and Precautions ( 5.4 )] . Venous Thromboembolism [see Warnings and Precautions ( 5.5 )] . Most common adverse reactions (incidence ≥20%) were diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, alopecia, and thrombocytopenia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety population described in the Warnings and Precautions reflect exposure to VERZENIO in 3691 patients from four clinical trials: monarchE, MONARCH 1, MONARCH 2, and MONARCH 3. The safety population includes exposure to VERZENIO as a single agent at 200 mg twice daily in 132 patients in MONARCH 1 and to VERZENIO at 150 mg twice daily in 3559 patients administered in combination with fulvestrant, tamoxifen, or an aromatase inhibitor in monarchE, MONARCH 2, and MONARCH 3. The median duration of exposure ranged from 4.5 months in MONARCH 1 to 24 months in monarchE. The most common adverse reactions (incidence ≥20%) across clinical trials were: diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, alopecia, and thrombocytopenia. Early Breast Cancer monarchE: VERZENIO in Combination with Tamoxifen or an Aromatase Inhibitor as Adjuvant Treatment Adult patients with HR-positive, HER2-negative, node-positive early breast cancer at a high risk of recurrence The safety of VERZENIO was evaluated in monarchE, a study of 5591 adult patients receiving VERZENIO plus endocrine therapy (tamoxifen or an aromatase inhibitor) or endocrine therapy (tamoxifen or an aromatase inhibitor) alone [see Clinical Studies ( 14.1 )]. Patients were randomly assigned to receive 150 mg of VERZENIO orally, twice daily, plus tamoxifen or an aromatase inhibitor, or tamoxifen or an aromatase inhibitor, for two years or until discontinuation criteria were met. The median duration of VERZENIO treatment was 24 months. The most frequently reported (≥5%) Grade 3 or 4 adverse reactions were neutropenia, leukopenia, diarrhea, and lymphopenia. Fatal adverse reactions occurred in 0.8% of patients who received VERZENIO plus endocrine therapy (tamoxifen or an aromatase inhibitor), including: cardiac failure (0.1%), cardiac arrest, myocardial infarction, ventricular fibrillation, cerebral hemorrhage, cerebrovascular accident, pneumonitis, hypoxia, diarrhea, and mesenteric artery thrombosis (0.03% each). Permanent VERZENIO treatment discontinuation due to an adverse reaction was reported in 19% of patients receiving VERZENIO, plus tamoxifen or an aromatase inhibitor. Of the patients receiving tamoxifen or an aromatase inhibitor, 1% permanently discontinued due to an adverse reaction. The most common adverse reactions leading to VERZENIO discontinuations were diarrhea (5%), fatigue (2%), and neutropenia (0.9%). Dose interruption of VERZENIO due to an adverse reaction occurred in 62% of patients receiving VERZENIO plus tamoxifen or aromatase inhibitors. Adverse reactions leading to VERZENIO dose interruptions in ≥5% of patients were diarrhea (20%), neutropenia (16%), leukopenia (7%), and fatigue (5%). Dose reductions of VERZENIO due to an adverse reaction occurred in 44% of patients receiving VERZENIO plus endocrine therapy (tamoxifen or an aromatase inhibitor). Adverse reactions leading to VERZENIO dose reductions in ≥5% were diarrhea (17%), neutropenia (8%), and fatigue (5%). The most common adverse reactions reported (≥20%) in the VERZENIO, plus tamoxifen or an aromatase inhibitor, arm and ≥2% higher than the tamoxifen or an aromatase inhibitor arm were: diarrhea, infections, neutropenia, fatigue, leukopenia, nausea, anemia, and headache. Adverse reactions are shown in Table 8 and laboratory abnormalities are shown in Table 9 . Table 8: Adverse Reactions (≥10%) of Patients Receiving VERZENIO Plus Tamoxifen or an Aromatase Inhibitor [with a Difference between Arms of ≥2%] in monarchE a Includes the following fatal adverse reactions: diarrhea (n=1), and infections (n=4) b Includes the following fatal adverse reactions: infections (n=5) c Includes mouth ulceration, mucosal inflammation, oropharyngeal pain, stomatitis. d Includes all reported preferred terms that are part of the Infections and Infestations system organ class. Most common infections (>5%) include upper respiratory tract infection, urinary tract infection, and nasopharyngitis. e Includes asthenia, fatigue. f Includes exfoliative rash, mucocutaneous rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculo-papular, rash maculovesicular, rash morbilliform, rash papular, rash papulosquamous, rash pruritic, rash vesicular, vulvovaginal rash. VERZENIO Plus Tamoxifen or an Aromatase Inhibitor N=2791 Tamoxifen or an Aromatase Inhibitor N=2800 All Grades a % Grade 3 % Grade 4 % All Grades b % Grade 3 % Grade 4 % Gastrointestinal Disorders Diarrhea 84 8 0 9 0.2 0 Nausea 30 0.5 0 9 <0.1 0 Vomiting 18 0.5 0 4.6 0.1 0 Stomatitis c 14 0.1 0 5 0 0 Infections and Infestations Infections d 51 4.9 0.6 39 2.7 0.1 General Disorders and Administration Site Conditions Fatigue e 41 2.9 0 18 0.1 0 Nervous System Disorders Headache 20 0.3 0 15 0.2 0 Dizziness 11 0.1 0 7 <0.1 0 Metabolism and Nutrition Disorders Decreased appetite 12 0.6 0 2.4 <0.1 0 Skin and Subcutaneous Tissue Disorders Rash f 11 0.4 0 4.5 0 0 Alopecia 11 0 0 2.7 0 0 Clinically relevant adverse reactions in <10% of patients who received VERZENIO in combination with tamoxifen or an aromatase inhibitor in monarchE include: Pruritus-9% Dyspepsia-8% Nail disorder-6% (includes nail bed disorder, nail bed inflammation, nail discoloration, nail disorder, nail dystrophy, nail pigmentation, nail ridging, nail toxicity, onychalgia, onychoclasis, onycholysis, onychomadesis) Lacrimation increased-6% Dysgeusia-5% Interstitial lung disease (ILD)/pneumonitis-3% (includes pneumonitis, radiation pneumonitis, interstitial lung disease, pulmonary fibrosis, organizing pneumonia, radiation fibrosis – lung, lung opacity, sarcoidosis) Venous thromboembolic events (VTEs)-3% (includes catheter site thrombosis, cerebral venous thrombosis, deep vein thrombosis, device related thrombosis, embolism, hepatic vein thrombosis, jugular vein occlusion, jugular vein thrombosis, ovarian vein thrombosis, portal vein thrombosis, pulmonary embolism, subclavian vein thrombosis, venous thrombosis limb) Table 9: Laboratory Abnormalities (≥10%) in Patients Receiving VERZENIO Plus Tamoxifen or an Aromatase Inhibitor [with a Difference between Arms of ≥2%] in monarchE VERZENIO Plus Tamoxifen or an Aromatase Inhibitor N=2791 Tamoxifen or an Aromatase Inhibitor N=2800 All Grades % Grade 3 % Grade 4 % All Grades % Grade 3 % Grade 4 % Creatinine increased 99 0.5 0 91 <0.1 0 White blood cell decreased 89 19 <0.1 28 1.1 0 Neutrophil count decreased 84 18 0.7 23 1.6 0.3 Anemia 68 1.0 0 17 0.1 0 Lymphocyte count decreased 59 13 0.2 24 2.4 0.1 Platelet count decreased 37 0.7 0.2 10 0.1 0.1 Alanine aminotransferase increased 37 2.5 <0.1 24 1.2 0 Aspartate aminotransferase increased 31 1.5 <0.1 18 0.9 0 Hypokalemia 11 1.2 0.1 3.8 0.1 0.1 Advanced or Metastatic Breast Cancer MONARCH 3: VERZENIO in Combination with an Aromatase Inhibitor (Anastrozole or Letrozole) as Initial Endocrine-Based Therapy Postmenopausal Women with HR-positive, HER2-negative locoregionally recurrent or metastatic breast cancer with no prior systemic therapy in this disease setting The safety of VERZENIO was evaluated in MONARCH 3, a study of 488 women receiving VERZENIO plus an aromatase inhibitor or placebo plus an aromatase inhibitor [see Clinical Studies ( 14.2 )]. Patients were randomly assigned to receive 150 mg of VERZENIO or placebo orally twice daily, plus physician's choice of anastrozole or letrozole once daily. Median duration of treatment was 15.1 months for the VERZENIO arm and 13.9 months for the placebo arm. The most frequently reported (≥5%) Grade 3 or 4 adverse reactions were neutropenia, diarrhea, leukopenia, increased ALT, and anemia. Deaths during treatment or during the 30-day follow up, regardless of causality, were reported in 11 cases (3%) of VERZENIO plus an aromatase inhibitor treated patients versus 3 cases (2%) of placebo plus an aromatase inhibitor treated patients. Causes of death for patients receiving VERZENIO plus an aromatase inhibitor included: 3 (0.9%) patient deaths due to underlying disease, 3 (0.9%) due to lung infection, 3 (0.9%) due to VTE, 1 (0.3%) due to pneumonitis, and 1 (0.3%) due to cerebral infarction. Permanent treatment discontinuation due to an adverse reaction was reported in 13% of patients receiving VERZENIO plus an aromatase inhibitor and in 3% of patients receiving placebo plus an aromatase inhibitor. Adverse reactions leading to permanent discontinuation for patients receiving VERZENIO plus an aromatase inhibitor were diarrhea (2%), ALT increased (2%), infection (1%), venous thromboembolic events (VTE) (1%), neutropenia (0.9%), renal impairment (0.9%), AST increased (0.6%), dyspnea (0.6%), pulmonary fibrosis (0.6%) and anemia, rash, weight decreased and thrombocytopenia (each 0.3%). Dose interruption of VERZENIO due to an adverse reaction occurred in 56% of patients receiving VERZENIO plus anastrozole or letrozole. Adverse reactions leading to VERZENIO dose interruptions in ≥5% of patients were neutropenia (16%) and diarrhea (15%). Dose reductions due to an adverse reaction occurred in 43% of patients receiving VERZENIO plus anastrozole or letrozole. Adverse reactions leading to dose reductions in ≥5% of patients were diarrhea and neutropenia. VERZENIO dose reductions due to diarrhea of any grade occurred in 13% of patients receiving VERZENIO plus an aromatase inhibitor compared to 2% of patients receiving placebo plus an aromatase inhibitor. VERZENIO dose reductions due to neutropenia of any grade occurred in 11% of patients receiving VERZENIO plus an aromatase inhibitor compared to 0.6% of patients receiving placebo plus an aromatase inhibitor. The most common adverse reactions reported (≥20%) in the VERZENIO arm and ≥2% than the placebo arm were: diarrhea, neutropenia, fatigue, infections, nausea, abdominal pain, anemia, vomiting, alopecia, decreased appetite, and leukopenia. Adverse reactions are shown in Table 10 and laboratory abnormalities in Table 11 . Diarrhea incidence was greatest during the first month of VERZENIO dosing. The median time to onset of the first diarrhea event was 8 days, and the median durations of diarrhea for Grades 2 and for Grade 3 were 11 days and 8 days, respectively. Most diarrhea events recovered or resolved (88%) with supportive treatment and/or dose reductions [see Dosage and Administration ( 2.2 ) and Patient Counseling Information ( 17 )] . Nineteen percent of patients with diarrhea required a dose omission and 13% required a dose reduction. The median time to the first dose reduction due to diarrhea was 38 days. Table 10: Adverse Reactions (≥10%) in Patients Receiving VERZENIO Plus Anastrozole or Letrozole [with a Difference between Arms of ≥2%] in MONARCH 3 a Includes all reported preferred terms that are part of the Infections and Infestations system organ class. Most common infections (>1%) include upper respiratory tract infection, lung infection, and pharyngitis. VERZENIO plus Anastrozole or Letrozole N=327 Placebo plus Anastrozole or Letrozole N=161 All Grades % Grade 3 % Grade 4 % All Grades % Grade 3 % Grade 4 % Gastrointestinal Disorders Diarrhea 81 9 0 30 1.2 0 Nausea 39 0.9 0 20 1.2 0 Abdominal pain 29 1.2 0 12 1.2 0 Vomiting 28 1.2 0 12 1.9 0 Constipation 16 0.6 0 12 0 0 Infections and Infestations Infections a 39 4.0 0.9 29 2.5 0.6 General Disorders and Administration Site Conditions Fatigue 40 1.8 0 32 0 0 Influenza like illness 10 0 0 8 0 0 Skin and Subcutaneous Tissue Disorders Alopecia 27 0 0 11 0 0 Rash 14 0.9 0 5 0 0 Pruritus 13 0 0 9 0 0 Metabolism and Nutrition Disorders Decreased appetite 24 1.2 0 9 0.6 0 Investigations Weight decreased 10 0.6 0 3.1 0.6 0 Respiratory, Thoracic, and Mediastinal Disorders Cough 13 0 0 9 0 0 Dyspnea 12 0.6 0.3 6 0.6 0 Nervous System Disorders Dizziness 11 0.3 0 9 0 0 Additional adverse reactions in MONARCH 3 include venous thromboembolic events (deep vein thrombosis, pulmonary embolism, and pelvic venous thrombosis), which were reported in 5% of patients treated with VERZENIO plus anastrozole or letrozole as compared to 0.6% of patients treated with anastrozole or letrozole plus placebo. Table 11: Laboratory Abnormalities (≥10%) in Patients Receiving VERZENIO Plus Anastrozole or Letrozole [with a Difference Between Arms of ≥2%] in MONARCH 3 VERZENIO plus Anastrozole or Letrozole N=327 Placebo plus Anastrozole or Letrozole N=161 Laboratory Abnormality All Grades % Grade 3 % Grade 4 % All Grades % Grade 3 % Grade 4 % Creatinine increased 98 2.2 0 84 0 0 White blood cell decreased 82 13 0 27 0.6 0 Anemia 82 1.6 0 28 0 0 Neutrophil count decreased 80 19 2.9 21 2.6 0 Lymphocyte count decreased 53 7 0.6 26 1.9 0 Platelet count decreased 36 1.3 0.6 12 0.6 0 Alanine aminotransferase increased 48 6 0.6 25 1.9 0 Aspartate aminotransferase increased 37 3.8 0 23 0.6 0 Creatinine Increased Abemaciclib has been shown to increase serum creatinine due to inhibition of renal tubular secretion transporters, without affecting glomerular function [see Clinical Pharmacology ( 12.3 )] . Across the clinical studies, increases in serum creatinine (mean increase, 0.2-0.3 mg/dL) occurred within the first 28-day cycle of VERZENIO dosing, remained elevated but stable through the treatment period, and were reversible upon treatment discontinuation. Alternative markers such as BUN, cystatin C, or calculated GFR, which are not based on creatinine, may be considered to determine whether renal function is impaired. MONARCH 2: VERZENIO in Combination with Fulvestrant Women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression on or after prior adjuvant or metastatic endocrine therapy The safety of VERZENIO (150 mg twice daily) plus fulvestrant (500 mg) versus placebo plus fulvestrant was evaluated in MONARCH 2 [see Clinical Studies ( 14.2 )] . The data described below reflect exposure to VERZENIO in 441 patients with HR-positive, HER2-negative advanced breast cancer who received at least one dose of VERZENIO plus fulvestrant in MONARCH 2. Median duration of treatment was 12 months for patients receiving VERZENIO plus fulvestrant and 8 months for patients receiving placebo plus fulvestrant. The most frequently reported (≥5%) Grade 3 or 4 adverse reactions were neutropenia, diarrhea, leukopenia, anemia, and infections. Deaths during treatment or during the 30-day follow up, regardless of causality, were reported in 18 cases (4%) of VERZENIO plus fulvestrant treated patients versus 10 cases (5%) of placebo plus fulvestrant treated patients. Causes of death for patients receiving VERZENIO plus fulvestrant included: 7 (2%) patient deaths due to underlying disease, 4 (0.9%) due to sepsis, 2 (0.5%) due to pneumonitis, 2 (0.5%) due to hepatotoxicity, and one (0.2%) due to cerebral infarction. Permanent study treatment discontinuation due to an adverse reaction were reported in 9% of patients receiving VERZENIO plus fulvestrant and in 3% of patients receiving placebo plus fulvestrant. Adverse reactions leading to permanent discontinuation for patients receiving VERZENIO plus fulvestrant were infection (2%), diarrhea (1%), hepatotoxicity (1%), fatigue (0.7%), nausea (0.2%), abdominal pain (0.2%), acute kidney injury (0.2%), and cerebral infarction (0.2%). Dose interruption of VERZENIO due to an adverse reaction occurred in 52% of patients receiving VERZENIO plus fulvestrant. Adverse reactions leading to VERZENIO dose interruptions in ≥5% of patients were diarrhea (19%) and neutropenia (16%). Dose reductions due to an adverse reaction occurred in 43% of patients receiving VERZENIO plus fulvestrant. Adverse reactions leading to reductions in ≥5% of patients were diarrhea and neutropenia. VERZENIO dose reductions due to diarrhea of any grade occurred in 19% of patients receiving VERZENIO plus fulvestrant compared to 0.4% of patients receiving placebo and fulvestrant. VERZENIO dose reductions due to neutropenia of any grade occurred in 10% of patients receiving VERZENIO plus fulvestrant compared to no patients receiving placebo plus fulvestrant. The most common adverse reactions reported (≥20%) in the VERZENIO arm were: diarrhea, fatigue, neutropenia, nausea, infections, abdominal pain, anemia, leukopenia, decreased appetite, vomiting, and headache. Adverse reactions are shown in Table 12 and laboratory abnormalities in Table 13 . Table 12: Adverse Reactions (≥10%) in Patients Receiving VERZENIO Plus Fulvestrant [with a Difference Between Arms of ≥2%] in MONARCH 2 a Includes abdominal pain, abdominal pain upper, abdominal pain lower, abdominal discomfort, abdominal tenderness. b Includes upper respiratory tract infection, urinary tract infection, lung infection, pharyngitis, conjunctivitis, sinusitis, vaginal infection, sepsis. c Includes asthenia, fatigue. VERZENIO plus Fulvestrant N=441 Placebo plus Fulvestrant N=223 All Grades % Grade 3 % Grade 4 % All Grades % Grade 3 % Grade 4 % Gastrointestinal Disorders Diarrhea 86 13 0 25 0.4 0 Nausea 45 2.7 0 23 0.9 0 Abdominal pain a 35 2.5 0 16 0.9 0 Vomiting 26 0.9 0 10 1.8 0 Stomatitis 15 0.5 0 10 0 0 Infections and Infestations Infections b 43 5 0.7 25 3.1 0.4 General Disorders and Administration Site Conditions Fatigue c 46 2.7 0 32 0.4 0 Edema peripheral 12 0 0 7 0 0 Pyrexia 11 0.5 0.2 6 0.4 0 Metabolism and Nutrition Disorders Decreased appetite 27 1.1 0 12 0.4 0 Respiratory, Thoracic and Mediastinal Disorders Cough 13 0 0 11 0 0 Skin and Subcutaneous Tissue Disorders Alopecia 16 0 0 1.8 0 0 Pruritus 13 0 0 6 0 0 Rash 11 1.1 0 4.5 0 0 Nervous System Disorders Headache 20 0.7 0 15 0.4 0 Dysgeusia 18 0 0 2.7 0 0 Dizziness 12 0.7 0 6 0 0 Investigations Weight decreased 10 0.2 0 2.2 0.4 0 Additional adverse reactions in MONARCH 2 include venous thromboembolic events (deep vein thrombosis, pulmonary embolism, cerebral venous sinus thrombosis, subclavian vein thrombosis, axillary vein thrombosis, and DVT inferior vena cava), which were reported in 5% of patients treated with VERZENIO plus fulvestrant as compared to 0.9% of patients treated with fulvestrant plus placebo. Table 13: Laboratory Abnormalities (≥10%) in Patients Receiving VERZENIO Plus Fulvestrant [with a Difference Between Arms of ≥2%]in MONARCH 2 VERZENIO plus Fulvestrant N=441 Placebo plus Fulvestrant N=223 All Grades % Grade 3 % Grade 4 % All Grades % Grade 3 % Grade 4 % Creatinine increased 98 1.2 0 74 0 0 White blood cell decreased 90 23 0.7 33 0.9 0 Neutrophil count decreased 87 29 3.5 30 3.7 0.5 Anemia 84 2.6 0 34 0.5 0 Lymphocyte count decreased 63 12 0.2 32 1.8 0 Platelet count decreased 53 0.9 1.2 15 0 0 Alanine aminotransferase increased 41 3.9 0.7 32 1.4 0 Aspartate aminotransferase increased 37 3.9 0 25 3.7 0.5 Creatinine Increased Abemaciclib has been shown to increase serum creatinine due to inhibition of renal tubular secretion transporters, without affecting glomerular function [see Clinical Pharmacology ( 12.3 )] . In clinical studies, increases in serum creatinine (mean increase, 0.2-0.3 mg/dL) occurred within the first 28-day cycle of VERZENIO dosing, remained elevated but stable through the treatment period, and were reversible upon treatment discontinuation. Alternative markers such as BUN, cystatin C, or calculated glomerular filtration rate (GFR), which are not based on creatinine, may be considered to determine whether renal function is impaired. MONARCH 1: VERZENIO Administered as a Monotherapy in Metastatic Breast Cancer Patients with HR-positive, HER2-negative breast cancer who received prior endocrine therapy and 1-2 chemotherapy regimens in the metastatic setting The safety of VERZENIO was evaluated in MONARCH 1, a single-arm, open-label, multicenter study in 132 women with measurable HR-positive, HER2-negative metastatic breast cancer [see Clinical Studies ( 14.2 )] . Patients received 200 mg VERZENIO orally twice daily until development of progressive disease or unmanageable toxicity. Median duration of treatment was 4.5 months. The most frequently reported (≥5%) Grade 3 or 4 adverse reactions were diarrhea, neutropenia, fatigue, and leukopenia. Deaths due to adverse reactions during treatment or during the 30-day follow up were reported in 2% of patients. Cause of death in these patients was due to infection (2 patients) or pneumonitis (1 patient). Ten patients (8%) discontinued study treatment from adverse reactions due to (1 patient each), abdominal pain, arterial thrombosis, aspartate aminotransferase (AST) increased, blood creatinine increased, chronic kidney disease, diarrhea, ECG QT prolonged, fatigue, hip fracture, and lymphopenia. Dose interruption of VERZENIO due to an adverse reaction occurred in 58% of patients. The most frequent (≥5%) adverse reactions leading to dose interruptions were diarrhea (24%), neutropenia (16%), fatigue (10%), vomiting (6%), and nausea (5%). Forty-nine percent of patients had dose reductions due to an adverse reaction. The most frequent adverse reactions that led to dose reductions were diarrhea (20%), neutropenia (11%), and fatigue (9%). The most common reported adverse reactions (≥20%) were: diarrhea, fatigue, nausea, decreased appetite, abdominal pain, neutropenia, vomiting, infections, anemia, headache, and thrombocytopenia. Adverse reactions are shown in Table 14 and laboratory abnormalities in Table 15 . Table 14: Adverse Reactions (≥10%) of Patients in MONARCH 1 a Includes asthenia, fatigue. VERZENIO N=132 All Grades % Grade 3 % Grade 4 % Gastrointestinal Disorders Diarrhea 90 20 0 Nausea 64 4.5 0 Abdominal pain 39 2.3 0 Vomiting 35 1.5 0 Constipation 17 0.8 0 Dry mouth 14 0 0 Stomatitis 14 0 0 Infections and Infestations Infections 31 4.5 0 General Disorders and Administration Site Conditions Fatigue a 65 13 0 Pyrexia 11 0 0 Metabolism and Nutrition Disorders Decreased appetite 45 3.0 0 Dehydration 10 2.3 0 Respiratory, Thoracic and Mediastinal Disorders Cough 19 0 0 Musculoskeletal and Connective Tissue Disorders Arthralgia 15 0 0 Nervous System Disorders Headache 20 0 0 Dysgeusia 12 0 0 Dizziness 11 0 0 Skin and Subcutaneous Tissue Disorders Alopecia 12 0 0 Investigations Weight decreased 14 0 0 Table 15: Laboratory Abnormalities for Patients Receiving VERZENIO in MONARCH 1 VERZENIO N=132 All Grades % Grade 3 % Grade 4 % Creatinine increased 99 0.8 0 White blood cell decreased 91 28 0 Neutrophil count decreased 88 22 4.6 Anemia 69 0 0 Lymphocyte count decreased 42 13 0.8 Platelet count decreased 41 2.3 0 ALT increased 31 3.1 0 AST increased 30 3.8 0 Creatinine Increased Abemaciclib has been shown to increase serum creatinine due to inhibition of renal tubular secretion transporters, without affecting glomerular function [see Clinical Pharmacology ( 12.3 )] . In clinical studies, increases in serum creatinine (mean increase, 0.2-0.3 mg/dL) occurred within the first 28-day cycle of VERZENIO dosing, remained elevated but stable through the treatment period, and were reversible upon treatment discontinuation. Alternative markers such as BUN, cystatin C, or calculated GFR, which are not based on creatinine, may be considered to determine whether renal function is impaired. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of VERZENIO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Respiratory disorders : Interstitial lung disease (ILD)/pneumonitis [see Warnings and Precautions ( 5.3 )] ."],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS CYP3A Inhibitors: Avoid concomitant use of ketoconazole. Reduce the VERZENIO dose with concomitant use of other strong and moderate CYP3A inhibitors. ( 2.2 , 7.1 ) CYP3A Inducers: Avoid concomitant use of strong and moderate CYP3A inducers. ( 7.1 ) 7.1 Effect of Other Drugs on VERZENIO CYP3A Inhibitors Strong and moderate CYP3A4 inhibitors increased the exposure of abemaciclib plus its active metabolites to a clinically meaningful extent and may lead to increased toxicity. Ketoconazole Avoid concomitant use of ketoconazole. Ketoconazole is predicted to increase the AUC of abemaciclib by up to 16-fold [see Clinical Pharmacology ( 12.3 )] . Other Strong CYP3A Inhibitors In patients with recommended starting doses of 200 mg twice daily or 150 mg twice daily, reduce the VERZENIO dose to 100 mg twice daily with concomitant use of strong CYP3A inhibitors other than ketoconazole. In patients who have had a dose reduction to 100 mg twice daily due to adverse reactions, further reduce the VERZENIO dose to 50 mg twice daily with concomitant use of strong CYP3A inhibitors. If a patient taking VERZENIO discontinues a strong CYP3A inhibitor, increase the VERZENIO dose (after 3-5 half-lives of the inhibitor) to the dose that was used before starting the inhibitor. Patients should avoid grapefruit products [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )] . Moderate CYP3A Inhibitors With concomitant use of moderate CYP3A inhibitors, monitor for adverse reactions and consider reducing the VERZENIO dose in 50 mg decrements as demonstrated in Table 1 , if necessary. Strong and Moderate CYP3A Inducers Coadministration of strong or moderate CYP3A inducers decreased the plasma concentrations of abemaciclib plus its active metabolites and may lead to reduced activity. Avoid concomitant use of strong or moderate CYP3A inducers and consider alternative agents [see Clinical Pharmacology ( 12.3 )] ."],"how_supplied_table":["
200 mg dose pack (14 tablets) – each blister pack contains 14 tablets (200 mg per tablet) (200 mg twice daily)
NDC 0002-6216-54
150 mg dose pack (14 tablets) – each blister pack contains 14 tablets (150 mg per tablet) (150 mg twice daily)
NDC 0002-5337-54
100 mg dose pack (14 tablets) – each blister pack contains 14 tablets (100 mg per tablet) (100 mg twice daily)
NDC 0002-4815-54
50 mg dose pack (14 tablets) – each blister pack contains 14 tablets (50 mg per tablet) (50 mg twice daily)
NDC 0002-4483-54
","
200 mg dose pack (14 tablets) – each blister pack contains 14 tablets (200 mg per tablet) (200 mg twice daily)
NDC 0002-6216-54
150 mg dose pack (14 tablets) – each blister pack contains 14 tablets (150 mg per tablet) (150 mg twice daily)
NDC 0002-5337-54
100 mg dose pack (14 tablets) – each blister pack contains 14 tablets (100 mg per tablet) (100 mg twice daily)
NDC 0002-4815-54
50 mg dose pack (14 tablets) – each blister pack contains 14 tablets (50 mg per tablet) (50 mg twice daily)
NDC 0002-4483-54
"],"mechanism_of_action":["12.1 Mechanism of Action Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These kinases are activated upon binding to D-cyclins. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation. In vitro, continuous exposure to abemaciclib inhibited Rb phosphorylation and blocked progression from G1 into S phase of the cell cycle, resulting in senescence and apoptosis. In breast cancer xenograft models, abemaciclib dosed daily without interruption as a single agent or in combination with antiestrogens resulted in reduction of tumor size."],"storage_and_handling":["Storage and Handling Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These kinases are activated upon binding to D-cyclins. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation. In vitro, continuous exposure to abemaciclib inhibited Rb phosphorylation and blocked progression from G1 into S phase of the cell cycle, resulting in senescence and apoptosis. In breast cancer xenograft models, abemaciclib dosed daily without interruption as a single agent or in combination with antiestrogens resulted in reduction of tumor size. 12.2 Pharmacodynamics Cardiac Electrophysiology Based on evaluation of the QTc interval in patients and in a healthy volunteer study, abemaciclib did not cause large mean increases (i.e., 20 ms) in the QTc interval. 12.3 Pharmacokinetics The pharmacokinetics of abemaciclib were characterized in patients with solid tumors, including breast cancer, and in healthy subjects. Following single and repeated twice daily dosing of 50 mg (0.3 times the approved recommended 150 mg dosage) to 200 mg of abemaciclib, the increase in plasma exposure (AUC) and C max was approximately dose proportional. Steady state was achieved within 5 days following repeated twice daily dosing, and the estimated geometric mean accumulation ratio was 2.3 (50% CV) and 3.2 (59% CV) based on C max and AUC, respectively. Absorption The absolute bioavailability of abemaciclib after a single oral dose of 200 mg is 45% (19% CV). The median T max of abemaciclib is 8.0 hours (range: 4.1-24.0 hours). Effect of Food A high-fat, high-calorie meal (approximately 800 to 1000 calories with 150 calories from protein, 250 calories from carbohydrate, and 500 to 600 calories from fat) administered to healthy subjects increased the AUC of abemaciclib plus its active metabolites by 9% and increased C max by 26%. Distribution In vitro, abemaciclib was bound to human plasma proteins, serum albumin, and alpha-1-acid glycoprotein in a concentration independent manner from 152 ng/mL to 5066 ng/mL. In a clinical study, the mean (standard deviation, SD) bound fraction was 96.3% (1.1) for abemaciclib, 93.4% (1.3) for M2, 96.8% (0.8) for M18, and 97.8% (0.6) for M20. The geometric mean systemic volume of distribution is approximately 690.3 L (49% CV). In patients with advanced cancer, including breast cancer, concentrations of abemaciclib and its active metabolites M2 and M20 in cerebrospinal fluid are comparable to unbound plasma concentrations. Elimination The geometric mean hepatic clearance (CL) of abemaciclib in patients was 26.0 L/h (51% CV), and the mean plasma elimination half-life for abemaciclib in patients was 18.3 hours (72% CV). Metabolism Hepatic metabolism is the main route of clearance for abemaciclib. Abemaciclib is metabolized to several metabolites primarily by cytochrome P450 (CYP) 3A4, with formation of N-desethylabemaciclib (M2) representing the major metabolism pathway. Additional metabolites include hydroxyabemaciclib (M20), hydroxy-N-desethylabemaciclib (M18), and an oxidative metabolite (M1). M2, M18, and M20 are equipotent to abemaciclib and their AUCs accounted for 25%, 13%, and 26% of the total circulating analytes in plasma, respectively. Excretion After a single 150 mg oral dose of radiolabeled abemaciclib, approximately 81% of the dose was recovered in feces and approximately 3% recovered in urine. The majority of the dose eliminated in feces was metabolites. Specific Populations Age, Gender, and Body Weight Based on a population pharmacokinetic analysis in patients with cancer, age (range 24-91 years), gender (134 males and 856 females), and body weight (range 36-175 kg) had no effect on the exposure of abemaciclib. Patients with Renal Impairment In a population pharmacokinetic analysis of 990 individuals, in which 381 individuals had mild renal impairment (60 mL/min ≤ CLcr <90 mL/min) and 126 individuals had moderate renal impairment (30 mL/min ≤ CLcr <60 mL/min), mild and moderate renal impairment had no effect on the exposure of abemaciclib [see Use in Specific Populations ( 8.6 )] . The effect of severe renal impairment (CLcr <30 mL/min) on pharmacokinetics of abemaciclib is unknown. Patients with Hepatic Impairment Following a single 200 mg oral dose of abemaciclib, the relative potency adjusted unbound AUC 0-INF of abemaciclib plus its active metabolites (M2, M18, M20) in plasma increased 1.2-fold in subjects with mild hepatic impairment (Child-Pugh A, n=9), 1.1-fold in subjects with moderate hepatic impairment (Child-Pugh B, n=10), and 2.4-fold in subjects with severe hepatic impairment (Child-Pugh C, n=6) relative to subjects with normal hepatic function (n=10) [see Use in Specific Populations ( 8.7 )] . In subjects with severe hepatic impairment, the mean plasma elimination half-life of abemaciclib increased to 55 hours compared to 24 hours in subjects with normal hepatic function. Drug Interaction Studies Effects of Other Drugs on Abemaciclib Strong CYP3A Inhibitors: Ketoconazole (a strong CYP3A inhibitor) is predicted to increase the AUC of abemaciclib by up to 16-fold. Coadministration of 500 mg twice daily doses of clarithromycin (a strong CYP3A inhibitor) with a single 50 mg dose of VERZENIO (0.3 times the approved recommended 150 mg dosage) increased the relative potency adjusted unbound AUC 0-INF of abemaciclib plus its active metabolites (M2, M18, and M20) by 2.5-fold relative to abemaciclib alone in cancer patients. Moderate CYP3A Inhibitors: Verapamil and diltiazem (moderate CYP3A inhibitors) are predicted to increase the relative potency adjusted unbound AUC of abemaciclib plus its active metabolites (M2, M18, and M20) by approximately 1.6-fold and 2.4-fold, respectively. Strong CYP3A Inducers: Coadministration of 600 mg daily doses of rifampin (a strong CYP3A inducer) with a single 200 mg dose of VERZENIO decreased the relative potency adjusted unbound AUC 0-INF of abemaciclib plus its active metabolites (M2, M18, and M20) by approximately 70% in healthy subjects. Moderate CYP3A Inducers: Efavirenz, bosentan, and modafinil (moderate CYP3A inducers) are predicted to decrease the relative potency adjusted unbound AUC of abemaciclib plus its active metabolites (M2, M18, and M20) by 53%, 41%, and 29%, respectively. Loperamide: Co-administration of a single 8 mg dose of loperamide with a single 400 mg dose of abemaciclib in healthy subjects increased the relative potency adjusted unbound AUC 0-INF of abemaciclib plus its active metabolites (M2 and M20) by 12%, which is not considered clinically relevant. Endocrine Therapies: In clinical studies in patients with breast cancer, there was no clinically relevant effect of fulvestrant, anastrozole, letrozole, exemestane, or tamoxifen on abemaciclib pharmacokinetics. Effects of Abemaciclib on Other Drugs Loperamide: In a clinical drug interaction study in healthy subjects, coadministration of a single 8 mg dose of loperamide with a single 400 mg abemaciclib (2.7 times the approved recommended 150 mg dosage) increased loperamide AUC 0-INF by 9% and C max by 35% relative to loperamide alone. These increases in loperamide exposure are not considered clinically relevant. Metformin: In a clinical drug interaction study in healthy subjects, coadministration of a single 1000 mg dose of metformin, a clinically relevant substrate of renal OCT2, MATE1, and MATE2-K transporters, with a single 400 mg dose of abemaciclib (2.7 times the approved recommended 150 mg dosage) increased metformin AUC 0-INF by 37% and C max by 22% relative to metformin alone. Abemaciclib reduced the renal clearance and renal secretion of metformin by 45% and 62%, respectively, relative to metformin alone, without any effect on glomerular filtration rate (GFR) as measured by iohexol clearance and serum cystatin C. Endocrine Therapies: In clinical studies in patients with breast cancer, there was no clinically relevant effect of abemaciclib on the pharmacokinetics of fulvestrant, anastrozole, letrozole, exemestane, or tamoxifen. CYP Metabolic Pathways: In a clinical drug interaction study in patients with cancer, multiple doses of abemaciclib (200 mg twice daily for 7 days) did not result in clinically meaningful changes in the pharmacokinetics of CYP1A2, CYP2C9, CYP2D6 and CYP3A4 substrates. Abemaciclib is a substrate of CYP3A4, and time-dependent changes in pharmacokinetics of abemaciclib as a result of autoinhibition of its metabolism were not observed. In Vitro Studies Transporter Systems: Abemaciclib and its major active metabolites inhibit the renal transporters OCT2, MATE1, and MATE2-K at concentrations achievable at the approved recommended dosage. The observed serum creatinine increase in clinical studies with abemaciclib is likely due to inhibition of tubular secretion of creatinine via OCT2, MATE1, and MATE2-K [see Adverse Effects ( 6.1 )] . Abemaciclib and its major metabolites at clinically relevant concentrations do not inhibit the hepatic uptake transporters OCT1, OATP1B1, and OATP1B3 or the renal uptake transporters OAT1 and OAT3. Abemaciclib is a substrate of P-gp and BCRP. Abemaciclib and its major active metabolites, M2 and M20, are not substrates of hepatic uptake transporters OCT1, organic anion transporting polypeptide 1B1 (OATP1B1), or OATP1B3. Abemaciclib inhibits P-gp and BCRP. The clinical consequences of this finding on sensitive P-gp and BCRP substrates are unknown. P-gp and BCRP Inhibitors: In vitro, abemaciclib is a substrate of P-gp and BCRP. The effect of P-gp or BCRP inhibitors on the pharmacokinetics of abemaciclib has not been studied."],"indications_and_usage":["1 INDICATIONS AND USAGE VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 ) 1.1 Early Breast Cancer VERZENIO ® (abemaciclib) is indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence [see Clinical Studies ( 14.1 )]. 1.2 Advanced or Metastatic Breast Cancer VERZENIO (abemaciclib) is indicated: in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Diarrhea: VERZENIO can cause severe cases of diarrhea, associated with dehydration and infection. Instruct patients at the first sign of loose stools to initiate antidiarrheal therapy, increase oral fluids, and notify their healthcare provider. ( 2.2 , 5.1 ) Neutropenia: Monitor complete blood counts prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. ( 2.2 , 5.2 ) Interstitial Lung Disease (ILD)/Pneumonitis: Severe and fatal cases of ILD/pneumonitis have been reported. Monitor for clinical symptoms or radiological changes indicative of ILD/pneumonitis. Permanently discontinue VERZENIO in all patients with Grade 3 or 4 ILD or pneumonitis. ( 2.2 , 5.3 ) Hepatotoxicity: Increases in serum transaminase levels have been observed. Perform liver function tests (LFTs) before initiating treatment with VERZENIO. Monitor LFTs every two weeks for the first two months, monthly for the next 2 months, and as clinically indicated. ( 2.2 , 5.4 ) Venous Thromboembolism: Monitor patients for signs and symptoms of thrombosis and pulmonary embolism and treat as medically appropriate. ( 2.2 , 5.5 ) Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ( 5.6 , 8.1 , 8.3 ) 5.1 Diarrhea Severe diarrhea associated with dehydration and infection occurred in patients treated with VERZENIO. Across four clinical trials in 3691 patients, diarrhea occurred in 81% to 90% of patients who received VERZENIO. Grade 3 diarrhea occurred in 8% to 20% of patients receiving VERZENIO [see Adverse Reactions ( 6.1 )]. Most patients experienced diarrhea during the first month of VERZENIO treatment. The median time to onset of the first diarrhea event ranged from 6 to 8 days; and the median duration of Grade 2 and Grade 3 diarrhea ranged from 6 to 11 days and 5 to 8 days, respectively. Across trials, 19% to 26% of patients with diarrhea required a VERZENIO dose interruption and 13% to 23% required a dose reduction. Instruct patients to start antidiarrheal therapy such as loperamide at the first sign of loose stools, increase oral fluids, and notify their healthcare provider for further instructions and appropriate follow up [see Patient Counseling Information ( 17 )]. For Grade 3 or 4 diarrhea, or diarrhea that requires hospitalization, discontinue VERZENIO until toxicity resolves to ≤Grade 1, and then resume VERZENIO at the next lower dose [see Dosage and Administration ( 2.2 )] . 5.2 Neutropenia Neutropenia, including febrile neutropenia and fatal neutropenic sepsis, occurred in patients treated with VERZENIO. Across four clinical trials in 3691 patients, neutropenia occurred in a 37% to 46% of patients receiving VERZENIO. A Grade ≥3 decrease in neutrophil count (based on laboratory findings) occurred in 19% to 32% of patients receiving VERZENIO. Across trials, the median time to the first episode of Grade ≥3 neutropenia ranged from 29 days to 33 days, and the median duration of Grade ≥3 neutropenia ranged from 11 days to 16 days [see Adverse Reactions ( 6.1 )] . Febrile neutropenia has been reported in <1% of patients exposed to VERZENIO across trials. Two deaths due to neutropenic sepsis were observed in MONARCH 2. Inform patients to promptly report any episodes of fever to their healthcare provider [see Patient Counseling Information ( 17 )] . Monitor complete blood counts prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia [see Dosage and Administration ( 2.2 )] . 5.3 Interstitial Lung Disease (ILD) or Pneumonitis Severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis can occur in patients treated with VERZENIO and other CDK4/6 inhibitors. In VERZENIO-treated patients in early breast cancer (monarchE, N=2791), 3% of patients experienced ILD or pneumonitis of any grade: 0.4% were Grade 3 or 4 and there was one fatality (0.1%). In VERZENIO-treated patients in advanced or metastatic breast cancer (N=900) (MONARCH 1, MONARCH 2, MONARCH 3), 3.3% of VERZENIO-treated patients had ILD or pneumonitis of any grade: 0.6% had Grade 3 or 4, and 0.4% had fatal outcomes. Additional cases of ILD or pneumonitis have been observed in the postmarketing setting, with fatalities reported [see Adverse Reactions ( 6.2 )] . Monitor patients for pulmonary symptoms indicative of ILD or pneumonitis. Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded by means of appropriate investigations. Dose interruption or dose reduction is recommended for patients who develop persistent or recurrent Grade 2 ILD or pneumonitis. Permanently discontinue VERZENIO in all patients with Grade 3 or 4 ILD or pneumonitis [see Dosage and Administration ( 2.2 )] . 5.4 Hepatotoxicity Grade ≥3 ALT (2% to 6%) and AST (2% to 3%) were reported in patients receiving VERZENIO. Across three clinical trials in 3559 patients (monarchE, MONARCH 2, MONARCH 3), the median time to onset of Grade ≥3 ALT increases ranged from 57 to 87 days and the median time to resolution to Grade <3 was 13 to 14 days. The median time to onset of Grade ≥3 AST increases ranged from 71 to 185 days and the median time to resolution to Grade <3 ranged from 11 to 15 days. Monitor liver function tests (LFTs) prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, dose reduction, dose discontinuation, or delay in starting treatment cycles is recommended for patients who develop persistent or recurrent Grade 2, or any Grade 3 or Grade 4 hepatic transaminase elevation [see Dosage and Administration ( 2.2 )] . 5.5 Venous Thromboembolism Across three clinical trials in 3559 patients (monarchE, MONARCH 2, MONARCH 3), venous thromboembolic events were reported in 2% to 5% of patients treated with VERZENIO. Venous thromboembolic events included deep vein thrombosis, pulmonary embolism, pelvic venous thrombosis, cerebral venous sinus thrombosis, subclavian and axillary vein thrombosis, and inferior vena cava thrombosis. In clinical trials, deaths due to venous thromboembolism have been reported in patients treated with VERZENIO. VERZENIO has not been studied in patients with early breast cancer who had a history of venous thromboembolism. Monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism and treat as medically appropriate. Dose interruption is recommended for early breast cancer patients with any grade venous thromboembolic event and for advanced or metastatic breast cancer patients with a Grade 3 or 4 venous thromboembolic event [see Dosage and Administration ( 2.2 )] . 5.6 Embryo-Fetal Toxicity Based on findings from animal studies and the mechanism of action, VERZENIO can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of abemaciclib to pregnant rats during the period of organogenesis caused teratogenicity and decreased fetal weight at maternal exposures that were similar to the human clinical exposure based on area under the curve (AUC) at the maximum recommended human dose. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with VERZENIO and for 3 weeks after the last dose [see Use in Specific Populations ( 8.1 , 8.3 ) and Clinical Pharmacology ( 12.1 )] ."],"clinical_studies_table":["
Table 16: Efficacy Results in monarchE in Cohort 1
Abbreviation: CI = confidence interval.
VERZENIO Plus Tamoxifen or an Aromatase Inhibitor N=2555Tamoxifen or an Aromatase Inhibitor N=2565
Invasive Disease–Free Survival (IDFS)
Number of patients with an event, n (%) 317 (12) 474 (18)
Hazard ratio (95% CI) 0.65 (0.57, 0.75)
IDFS at 48 months, % (95% CI)85.5 (83.8, 87.0) 78.6 (76.7, 80.4)
","
Table 17: Efficacy Results in MONARCH 3 (Investigator Assessment, Intent-to-Treat Population)
Abbreviations: CI = confidence interval; OS = overall survival; NR = not reached; NS = not statistically significant.
a Complete response + partial response.
b Based upon confirmed responses.
VERZENIO plus Anastrozole or LetrozolePlacebo plus Anastrozole or Letrozole
Progression-Free SurvivalN=328N=165
Number of patients with an event, n (%) 138 (42) 108 (65)
Median in months (95% CI) 28.2 (23.5, NR) 14.8 (11.2, 19.2)
Hazard ratio (95% CI) 0.54 (0.42, 0.70)
p-value <0.0001
Overall SurvivalN=328N=165
Number of patients with an event, n (%) 198 (60) 116 (70)
Median in months (95% CI) 66.8 (59.2, 74.8) 53.7 (44.7, 59.3)
Hazard ratio (95% CI) 0.80 (0.64, 1.02)
p-value NS
Objective Response for Patients with Measurable DiseaseaN=267N=132
Objective response rate n (%)a,b148 (55) 53 (40)
95% CI 49, 61 32, 49
","
Table 18: Efficacy Results in MONARCH 2 (Intent-to-Treat Population)
Abbreviation: CI = confidence interval, OS = overall survival.
a Stratified by disease site (visceral metastases vs. bone-only metastases vs. other) and endocrine therapy resistance (primary resistance vs. secondary resistance)
b Data from a pre-specified interim analysis (77% of the number of events needed for the planned final analysis) with the p-value compared with the allocated alpha of 0.021.
c Complete response + partial response.
VERZENIO plus FulvestrantPlacebo plus Fulvestrant
Progression-Free Survival (Investigator Assessment)N=446N=223
Number of patients with an event n (%) 222 (50) 157 (70)
Median in months (95% CI) 16.4 (14.4, 19.3) 9.3 (7.4, 12.7)
Hazard ratio (95% CI)a0.55 (0.45, 0.68)
p-valueap<.0001
Overall Survivalb
Number of deaths n (%) 211 (47) 127 (57)
Median OS in months (95% CI) 46.7 (39.2, 52.2) 37.3 (34.4, 43.2)
Hazard ratio (95% CI)a0.76 (0.61, 0.95)
p-valueap=.0137
Objective Response for Patients with Measurable DiseaseN=318N=164
Objective response rate n (%)c153 (48) 35 (21)
95% CI 43, 54 15, 28
","
Table 19: Efficacy Results in MONARCH 1 (Intent-to-Treat Population)
Abbreviations: CI = confidence interval, NR = not reached.
a All responses were partial responses.
b Based upon confirmed responses.
VERZENIO 200 mg N=132
Investigator AssessedIndependent Review
Objective Response Ratea,b, n (%)26 (20) 23 (17)
95% CI 13, 28 11, 25
Median Duration of Response in months8.6 7.2
95% CI 5.8, 10.2 5.6, NR
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Abemaciclib was assessed for carcinogenicity in a 2-year rat study. Abemaciclib was not carcinogenic in male and female rats at oral doses up to 3 mg/kg/day (approximately 1 time the exposure at the maximum recommended human dose based on AUC). Abemaciclib and its active human metabolites M2 and M20 were not mutagenic in a bacterial reverse mutation (Ames) assay or clastogenic in an in vitro chromosomal aberration assay in Chinese hamster ovary cells or human peripheral blood lymphocytes. Abemaciclib, M2, and M20 were not clastogenic in an in vivo rat bone marrow micronucleus assay. Abemaciclib may impair fertility in males of reproductive potential. In repeat-dose toxicity studies up to 3-months duration, abemaciclib-related findings in the testis, epididymis, prostate, and seminal vesicle at doses ≥10 mg/kg/day in rats and ≥0.3 mg/kg/day in dogs included decreased organ weights, intratubular cellular debris, hypospermia, tubular dilatation, atrophy, and degeneration/necrosis. These doses in rats and dogs resulted in approximately 2 and 0.02 times, respectively, the exposure (AUC) in humans at the maximum recommended human dose. In a rat male fertility study, abemaciclib had no effects on mating and fertility at oral doses up to 10 mg/kg/day (approximately 2 times the exposure at the maximum recommended human dose based on AUC). In a rat female fertility and early embryonic development study, abemaciclib did not affect mating and fertility at doses up to 20 mg/kg/day (approximately 3 times the exposure at the maximum recommended human dose based on AUC). 13.2 Animal Toxicology and/or Pharmacology In repeat-dose toxicity studies up to 6-months duration, oral administration of abemaciclib resulted in retinal atrophy of the eyes in mice at a dose of 150 mg/kg/day (approximately 10 times the exposure at the maximum recommended human dose based on AUC) and in rats at a dose of 30 mg/kg/day (approximately 5 times the exposure at the maximum recommended human dose based on AUC). In a 2-year rat carcinogenicity study, oral administration of abemaciclib resulted in retinal atrophy in the eyes at doses ≥0.3 mg/kg/day (approximately 0.05 times the exposure at the maximum recommended human dose based on AUC)."],"adverse_reactions_table":["
Table 8: Adverse Reactions (≥10%) of Patients Receiving VERZENIO Plus Tamoxifen or an Aromatase Inhibitor [with a Difference between Arms of ≥2%] in monarchE
a Includes the following fatal adverse reactions: diarrhea (n=1), and infections (n=4)
b Includes the following fatal adverse reactions: infections (n=5)
c Includes mouth ulceration, mucosal inflammation, oropharyngeal pain, stomatitis.
d Includes all reported preferred terms that are part of the Infections and Infestations system organ class. Most common infections (>5%) include upper respiratory tract infection, urinary tract infection, and nasopharyngitis.
e Includes asthenia, fatigue.
f Includes exfoliative rash, mucocutaneous rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculo-papular, rash maculovesicular, rash morbilliform, rash papular, rash papulosquamous, rash pruritic, rash vesicular, vulvovaginal rash.
VERZENIO Plus Tamoxifen or an Aromatase Inhibitor N=2791Tamoxifen or an Aromatase Inhibitor N=2800
All Gradesa %Grade 3 %Grade 4 %All Gradesb %Grade 3 %Grade 4 %
Gastrointestinal Disorders
Diarrhea 84 8 0 9 0.2 0
Nausea 30 0.5 0 9 <0.1 0
Vomiting 18 0.5 0 4.6 0.1 0
Stomatitisc14 0.1 0 5 0 0
Infections and Infestations
Infectionsd51 4.9 0.6 39 2.7 0.1
General Disorders and Administration Site Conditions
Fatiguee41 2.9 0 18 0.1 0
Nervous System Disorders
Headache 20 0.3 0 15 0.2 0
Dizziness 11 0.1 0 7 <0.1 0
Metabolism and Nutrition Disorders
Decreased appetite 12 0.6 0 2.4 <0.1 0
Skin and Subcutaneous Tissue Disorders
Rashf11 0.4 0 4.5 0 0
Alopecia 11 0 0 2.7 0 0
","
Table 9: Laboratory Abnormalities (≥10%) in Patients Receiving VERZENIO Plus Tamoxifen or an Aromatase Inhibitor [with a Difference between Arms of ≥2%] in monarchE
VERZENIO Plus Tamoxifen or an Aromatase Inhibitor N=2791Tamoxifen or an Aromatase Inhibitor N=2800
All Grades %Grade 3 %Grade 4 %All Grades %Grade 3 %Grade 4 %
Creatinine increased 99 0.5 0 91 <0.1 0
White blood cell decreased 89 19 <0.1 28 1.1 0
Neutrophil count decreased 84 18 0.7 23 1.6 0.3
Anemia 68 1.0 0 17 0.1 0
Lymphocyte count decreased 59 13 0.2 24 2.4 0.1
Platelet count decreased 37 0.7 0.2 10 0.1 0.1
Alanine aminotransferase increased 37 2.5 <0.1 24 1.2 0
Aspartate aminotransferase increased 31 1.5 <0.1 18 0.9 0
Hypokalemia 11 1.2 0.1 3.8 0.1 0.1
","
Table 10: Adverse Reactions (≥10%) in Patients Receiving VERZENIO Plus Anastrozole or Letrozole [with a Difference between Arms of ≥2%] in MONARCH 3
a Includes all reported preferred terms that are part of the Infections and Infestations system organ class. Most common infections (>1%) include upper respiratory tract infection, lung infection, and pharyngitis.
VERZENIO plus Anastrozole or Letrozole N=327Placebo plus Anastrozole or Letrozole N=161
All Grades %Grade 3 %Grade 4 %All Grades %Grade 3 %Grade 4 %
Gastrointestinal Disorders
Diarrhea 81 9 0 30 1.2 0
Nausea 39 0.9 0 20 1.2 0
Abdominal pain 29 1.2 0 12 1.2 0
Vomiting 28 1.2 0 12 1.9 0
Constipation 16 0.6 0 12 0 0
Infections and Infestations
Infectionsa39 4.0 0.9 29 2.5 0.6
General Disorders and Administration Site Conditions
Fatigue 40 1.8 0 32 0 0
Influenza like illness 10 0 0 8 0 0
Skin and Subcutaneous Tissue Disorders
Alopecia 27 0 0 11 0 0
Rash 14 0.9 0 5 0 0
Pruritus 13 0 0 9 0 0
Metabolism and Nutrition Disorders
Decreased appetite 24 1.2 0 9 0.6 0
Investigations
Weight decreased 10 0.6 0 3.1 0.6 0
Respiratory, Thoracic, and Mediastinal Disorders
Cough 13 0 0 9 0 0
Dyspnea 12 0.6 0.3 6 0.6 0
Nervous System Disorders
Dizziness 11 0.3 0 9 0 0
","
Table 11: Laboratory Abnormalities (≥10%) in Patients Receiving VERZENIO Plus Anastrozole or Letrozole [with a Difference Between Arms of ≥2%] in MONARCH 3
VERZENIO plus Anastrozole or Letrozole N=327Placebo plus Anastrozole or Letrozole N=161
Laboratory AbnormalityAll Grades %Grade 3 %Grade 4 %All Grades %Grade 3 %Grade 4 %
Creatinine increased 98 2.2 0 84 0 0
White blood cell decreased 82 13 0 27 0.6 0
Anemia 82 1.6 0 28 0 0
Neutrophil count decreased 80 19 2.9 21 2.6 0
Lymphocyte count decreased 53 7 0.6 26 1.9 0
Platelet count decreased 36 1.3 0.6 12 0.6 0
Alanine aminotransferase increased 48 6 0.6 25 1.9 0
Aspartate aminotransferase increased 37 3.8 0 23 0.6 0
","
Table 12: Adverse Reactions (≥10%) in Patients Receiving VERZENIO Plus Fulvestrant [with a Difference Between Arms of ≥2%] in MONARCH 2
a Includes abdominal pain, abdominal pain upper, abdominal pain lower, abdominal discomfort, abdominal tenderness.
b Includes upper respiratory tract infection, urinary tract infection, lung infection, pharyngitis, conjunctivitis, sinusitis, vaginal infection, sepsis.
c Includes asthenia, fatigue.
VERZENIO plus Fulvestrant N=441Placebo plus Fulvestrant N=223
All Grades %Grade 3 %Grade 4 %All Grades %Grade 3 %Grade 4 %
Gastrointestinal Disorders
Diarrhea 86 13 0 25 0.4 0
Nausea 45 2.7 0 23 0.9 0
Abdominal paina35 2.5 0 16 0.9 0
Vomiting 26 0.9 0 10 1.8 0
Stomatitis 15 0.5 0 10 0 0
Infections and Infestations
Infectionsb43 5 0.7 25 3.1 0.4
General Disorders and Administration Site Conditions
Fatiguec46 2.7 0 32 0.4 0
Edema peripheral 12 0 0 7 0 0
Pyrexia 11 0.5 0.2 6 0.4 0
Metabolism and Nutrition Disorders
Decreased appetite 27 1.1 0 12 0.4 0
Respiratory, Thoracic and Mediastinal Disorders
Cough 13 0 0 11 0 0
Skin and Subcutaneous Tissue Disorders
Alopecia 16 0 0 1.8 0 0
Pruritus 13 0 0 6 0 0
Rash 11 1.1 0 4.5 0 0
Nervous System Disorders
Headache 20 0.7 0 15 0.4 0
Dysgeusia 18 0 0 2.7 0 0
Dizziness 12 0.7 0 6 0 0
Investigations
Weight decreased 10 0.2 0 2.2 0.4 0
","
Table 13: Laboratory Abnormalities (≥10%) in Patients Receiving VERZENIO Plus Fulvestrant [with a Difference Between Arms of ≥2%]in MONARCH 2
VERZENIO plus Fulvestrant N=441Placebo plus Fulvestrant N=223
All Grades %Grade 3 %Grade 4 %All Grades %Grade 3 %Grade 4 %
Creatinine increased 98 1.2 0 74 0 0
White blood cell decreased 90 23 0.7 33 0.9 0
Neutrophil count decreased 87 29 3.5 30 3.7 0.5
Anemia 84 2.6 0 34 0.5 0
Lymphocyte count decreased 63 12 0.2 32 1.8 0
Platelet count decreased 53 0.9 1.2 15 0 0
Alanine aminotransferase increased 41 3.9 0.7 32 1.4 0
Aspartate aminotransferase increased 37 3.9 0 25 3.7 0.5
","
Table 14: Adverse Reactions (≥10%) of Patients in MONARCH 1
a Includes asthenia, fatigue.
VERZENIO N=132
All Grades %Grade 3 %Grade 4 %
Gastrointestinal Disorders
Diarrhea 90 20 0
Nausea 64 4.5 0
Abdominal pain 39 2.3 0
Vomiting 35 1.5 0
Constipation 17 0.8 0
Dry mouth 14 0 0
Stomatitis 14 0 0
Infections and Infestations
Infections 31 4.5 0
General Disorders and Administration Site Conditions
Fatiguea65 13 0
Pyrexia 11 0 0
Metabolism and Nutrition Disorders
Decreased appetite 45 3.0 0
Dehydration 10 2.3 0
Respiratory, Thoracic and Mediastinal Disorders
Cough 19 0 0
Musculoskeletal and Connective Tissue Disorders
Arthralgia 15 0 0
Nervous System Disorders
Headache 20 0 0
Dysgeusia 12 0 0
Dizziness 11 0 0
Skin and Subcutaneous Tissue Disorders
Alopecia 12 0 0
Investigations
Weight decreased 14 0 0
","
Table 15: Laboratory Abnormalities for Patients Receiving VERZENIO in MONARCH 1
VERZENIO N=132
All Grades %Grade 3 %Grade 4 %
Creatinine increased 99 0.8 0
White blood cell decreased 91 28 0
Neutrophil count decreased 88 22 4.6
Anemia 69 0 0
Lymphocyte count decreased 42 13 0.8
Platelet count decreased 41 2.3 0
ALT increased 31 3.1 0
AST increased 30 3.8 0
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Diarrhea VERZENIO may cause diarrhea, which may be severe in some cases [see Warnings and Precautions ( 5.1 )] . Early identification and intervention is critical for the optimal management of diarrhea. Instruct patients that at the first sign of loose stools, they should start antidiarrheal therapy (for example, loperamide) and notify their healthcare provider for further instructions and appropriate follow up. Encourage patients to increase oral fluids. If diarrhea does not resolve with antidiarrheal therapy within 24 hours to ≤Grade 1, suspend VERZENIO dosing [see Dosage and Administration ( 2.2 )] . Neutropenia Advise patients of the possibility of developing neutropenia and to immediately contact their healthcare provider should they develop a fever, particularly in association with any signs of infection [see Warnings and Precautions ( 5.2 )] . Interstitial Lung Disease/Pneumonitis Advise patients to immediately report new or worsening respiratory symptoms [see Warnings and Precautions ( 5.3 )] . Hepatotoxicity Inform patients of the signs and symptoms of hepatotoxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity [see Warnings and Precautions ( 5.4 )] . Venous Thromboembolism Advise patients to immediately report any signs or symptoms of thromboembolism such as pain or swelling in an extremity, shortness of breath, chest pain, tachypnea, and tachycardia [see Warnings and Precautions ( 5.5 )] . Embryo-Fetal Toxicity Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions ( 5.6 ) and Use in Specific Populations ( 8.1 )] . Advise females of reproductive potential to use effective contraception during VERZENIO treatment and for 3 weeks after the last dose [see Use in Specific Populations ( 8.1 , 8.3 )] . Lactation Advise lactating women not to breastfeed during VERZENIO treatment and for at least 3 weeks after the last dose [see Use in Specific Populations ( 8.2 )] . Infertility Inform males of reproductive potential that VERZENIO may impair fertility [see Use in Specific Populations ( 8.3 )] . Drug Interactions Inform patients to avoid concomitant use of ketoconazole. Dose reduction may be required for other strong CYP3A inhibitors or for moderate CYP3A inhibitors [see Dosage and Administration ( 2.2 ) and Drug Interactions ( 7 )] . Grapefruit may interact with VERZENIO. Advise patients not to consume grapefruit products while on treatment with VERZENIO. Advise patients to avoid concomitant use of strong and moderate CYP3A inducers and to consider alternative agents [see Dosage and Administration ( 2.2 ) and Drug Interactions ( 7 )] . Advise patients to inform their healthcare providers of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products [see Dosage and Administration ( 2.2 ) and Drug Interactions ( 7 )] . Dosing Instruct patients to take the doses of VERZENIO at approximately the same times every day and to swallow whole (do not chew, crush, or split them prior to swallowing) [see Dosage and Administration ( 2.1 )] . If patient vomits or misses a dose, advise the patient to take the next prescribed dose at the usual time [see Dosage and Administration ( 2.1 )] . Advise the patient that VERZENIO may be taken with or without food [see Dosage and Administration 2.1 )] . Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA Copyright © 2017, 2025, Eli Lilly and Company. All rights reserved. VER-0010-USPI-20250227"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION VERZENIO tablets are taken orally with or without food. ( 2.1 ) Recommended starting dose in combination with fulvestrant, tamoxifen, or an aromatase inhibitor: 150 mg twice daily. ( 2.1 ) Recommended starting dose as monotherapy: 200 mg twice daily. ( 2.1 ) Dosing interruption and/or dose reductions may be required based on individual safety and tolerability. ( 2.2 ) 2.1 Recommended Dose and Schedule When used in combination with fulvestrant, tamoxifen, or an aromatase inhibitor, the recommended dose of VERZENIO is 150 mg taken orally twice daily. Refer to the Full Prescribing Information for the recommended dose of the fulvestrant, tamoxifen, or aromatase inhibitor being used. Pre/perimenopausal women and men treated with the combination of VERZENIO plus an aromatase inhibitor should be treated with a gonadotropin-releasing hormone agonist (GnRH) according to current clinical practice standards. Pre/perimenopausal women treated with the combination of VERZENIO plus fulvestrant should be treated with a GnRH according to current clinical practice standards When used as monotherapy, the recommended dose of VERZENIO is 200 mg taken orally twice daily. For early breast cancer, continue VERZENIO until completion of 2 years of treatment or until disease recurrence, or unacceptable toxicity. For advanced or metastatic breast cancer, continue treatment until disease progression or unacceptable toxicity. VERZENIO may be taken with or without food [see Clinical Pharmacology ( 12.3 )] . Instruct patients to take their doses of VERZENIO at approximately the same times every day. If the patient vomits or misses a dose of VERZENIO, instruct the patient to take the next dose at its scheduled time. Instruct patients to swallow VERZENIO tablets whole and not to chew, crush, or split tablets before swallowing. Instruct patients not to ingest VERZENIO tablets if broken, cracked, or otherwise not intact. 2.2 Dose Modification Dose Modifications for Adverse Reactions The recommended VERZENIO dose modifications for adverse reactions are provided in Tables 1 - 7 . Discontinue VERZENIO for patients unable to tolerate 50 mg twice daily. Table 1: VERZENIO Dose Modification — Adverse Reactions Dose Level VERZENIO Dose Combination with Fulvestrant, Tamoxifen, or an Aromatase Inhibitor VERZENIO Dose for Monotherapy Recommended starting dose 150 mg twice daily 200 mg twice daily First dose reduction 100 mg twice daily 150 mg twice daily Second dose reduction 50 mg twice daily 100 mg twice daily Third dose reduction not applicable 50 mg twice daily Table 2: VERZENIO Dose Modification and Management — Hematologic Toxicities a Abbreviation: CTCAE = Common Terminology Criteria for Adverse Events. a If blood cell growth factors are required, suspend VERZENIO dose for at least 48 hours after the last dose of blood cell growth factor and until toxicity resolves to ≤Grade 2. Resume at next lower dose unless already performed for the toxicity that led to the use of the growth factor. Growth factor use as per current treatment guidelines. Monitor complete blood counts prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. CTCAE Grade VERZENIO Dose Modifications Grade 1 or 2 No dose modification is required. Grade 3 Suspend dose until toxicity resolves to ≤Grade 2. Dose reduction is not required. Grade 3 recurrent, or Grade 4 Suspend dose until toxicity resolves to ≤Grade 2. Resume at next lower dose . Table 3: VERZENIO Dose Modification and Management — Diarrhea At the first sign of loose stools, start treatment with antidiarrheal agents and increase intake of oral fluids. CTCAE Grade VERZENIO Dose Modifications Grade 1 No dose modification is required. Grade 2 If toxicity does not resolve within 24 hours to ≤Grade 1, suspend dose until resolution. No dose reduction is required. Grade 2 that persists or recurs after resuming the same dose despite maximal supportive measures Suspend dose until toxicity resolves to ≤Grade 1. Resume at next lower dose . Grade 3 or 4 or requires hospitalization Suspend dose until toxicity resolves to ≤Grade 1. Resume at next lower dose . Table 4: VERZENIO Dose Modification and Management — Hepatotoxicity Abbreviations: ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN = upper limit of normal. Monitor ALT, AST, and serum bilirubin prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. CTCAE Grade for ALT and AST VERZENIO Dose Modifications Grade 1 (>ULN-3.0 x ULN) Grade 2 (>3.0-5.0 x ULN), WITHOUT increase in total bilirubin above 2 x ULN No dose modification is required. Persistent or Recurrent Grade 2, or Grade 3 (>5.0-20.0 x ULN), WITHOUT increase in total bilirubin above 2 x ULN Suspend dose until toxicity resolves to baseline or Grade 1. Resume at next lower dose. Elevation in AST and/or ALT >3 x ULN WITH total bilirubin >2 x ULN, in the absence of cholestasis Discontinue VERZENIO. Grade 4 (>20.0 x ULN) Discontinue VERZENIO. Table 5: VERZENIO Dose Modification and Management — Interstitial Lung Disease/Pneumonitis CTCAE Grade VERZENIO Dose Modifications Grade 1 or 2 No dose modification is required. Persistent or recurrent Grade 2 toxicity that does not resolve with maximal supportive measures within 7 days to baseline or Grade 1 Suspend dose until toxicity resolves to baseline or ≤Grade 1. Resume at next lower dose . Grade 3 or 4 Discontinue VERZENIO. Table 6: VERZENIO Dose Modification and Management — Venous Thromboembolic Events (VTEs) CTCAE Grade VERZENIO Dose Modifications Early Breast Cancer Any Grade Suspend dose and treat as clinically indicated. Resume VERZENIO when the patient is clinically stable. Advanced or Metastatic Breast Cancer Grade 1 or 2 No dose modification is required. Grade 3 or 4 Suspend dose and treat as clinically indicated. Resume VERZENIO when the patient is clinically stable. Table 7: VERZENIO Dose Modification and Management — Other Toxicities a a Excluding diarrhea, hematologic toxicity, hepatotoxicity, ILD/pneumonitis, and VTEs. CTCAE Grade VERZENIO Dose Modifications Grade 1 or 2 No dose modification is required. Persistent or recurrent Grade 2 toxicity that does not resolve with maximal supportive measures within 7 days to baseline or Grade 1 Suspend dose until toxicity resolves to baseline or ≤Grade 1. Resume at next lower dose . Grade 3 or 4 Suspend dose until toxicity resolves to baseline or ≤Grade 1. Resume at next lower dose . Refer to the Full Prescribing Information for coadministered fulvestrant, tamoxifen, or an aromatase inhibitor for dose modifications and other relevant safety information. Dose Modification for Use with Strong and Moderate CYP3A Inhibitors Avoid concomitant use of the strong CYP3A inhibitor ketoconazole. With concomitant use of strong CYP3A inhibitors other than ketoconazole, in patients with recommended starting doses of 200 mg twice daily or 150 mg twice daily, reduce the VERZENIO dose to 100 mg twice daily. In patients who have had a dose reduction to 100 mg twice daily due to adverse reactions, further reduce the VERZENIO dose to 50 mg twice daily. If a patient taking VERZENIO discontinues a CYP3A inhibitor, increase the VERZENIO dose (after 3-5 half-lives of the inhibitor) to the dose that was used before starting the strong inhibitor [see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 )]. With concomitant use of moderate CYP3A inhibitors, monitor for adverse reactions and consider reducing the VERZENIO dose in 50 mg decrements as demonstrated in Table 1 , if necessary. Dose Modification for Patients with Severe Hepatic Impairment For patients with severe hepatic impairment (Child Pugh-C), reduce the VERZENIO dosing frequency to once daily [see Use in Specific Populations ( 8.7 ) and Clinical Pharmacology ( 12.3 )]. Refer to the Full Prescribing Information for the coadministered fulvestrant, tamoxifen, or aromatase inhibitor for dose modification requirements for severe hepatic impairment."],"spl_product_data_elements":["Verzenio abemaciclib abemaciclib abemaciclib Microcrystalline Cellulose Lactose Monohydrate Croscarmellose Sodium Silicon Dioxide Sodium Stearyl Fumarate Water Polyvinyl Alcohol, Unspecified Polyethylene Glycol, Unspecified Titanium Dioxide Talc Ferric Oxide Yellow Ferric Oxide Red beige modified oval Lilly;50 Verzenio abemaciclib abemaciclib abemaciclib Microcrystalline Cellulose Lactose Monohydrate Croscarmellose Sodium Silicon Dioxide Sodium Stearyl Fumarate Water Polyvinyl Alcohol, Unspecified Polyethylene Glycol, Unspecified Titanium Dioxide Talc white modified oval Lilly;100 Verzenio abemaciclib abemaciclib abemaciclib Microcrystalline Cellulose Lactose Monohydrate Croscarmellose Sodium Silicon Dioxide Sodium Stearyl Fumarate Water Polyvinyl Alcohol, Unspecified Polyethylene Glycol, Unspecified Titanium Dioxide Talc Ferric Oxide Yellow yellow modified oval Lilly;150 Verzenio abemaciclib abemaciclib abemaciclib Microcrystalline Cellulose Lactose Monohydrate Croscarmellose Sodium Silicon Dioxide Sodium Stearyl Fumarate Water Polyvinyl Alcohol, Unspecified Polyethylene Glycol, Unspecified Titanium Dioxide Talc Ferric Oxide Yellow Ferric Oxide Red beige modified oval Lilly;200"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS 50 mg tablets: oval beige tablet with “Lilly” debossed on one side and “50” on the other side. 100 mg tablets: oval white to practically white tablet with “Lilly” debossed on one side and “100” on the other side. 150 mg tablets: oval yellow tablet with “Lilly” debossed on one side and “150” on the other side. 200 mg tablets: oval beige tablet with “Lilly” debossed on one side and “200” on the other side. Tablets: 50 mg, 100 mg, 150 mg, and 200 mg. ( 3 )"],"spl_patient_package_insert":["This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: March-2023 PATIENT INFORMATION VERZENIO ® (ver-ZEN-ee-oh) (abemaciclib) tablets What is the most important information I should know about VERZENIO? VERZENIO may cause serious side effects including: Diarrhea . Diarrhea is common with VERZENIO treatment and may sometimes be severe. Diarrhea may cause you to develop dehydration or an infection. The most common time to develop diarrhea is during the first month of VERZENIO treatment. If you develop diarrhea during treatment with VERZENIO, your healthcare provider may tell you to temporarily stop taking VERZENIO, stop your treatment, or decrease your dose. – If you have any loose stools, start taking an antidiarrheal medicine (such as loperamide), drink more fluids, and tell your healthcare provider right away. Low white blood cell counts (neutropenia). Low white blood cell counts are common during treatment with VERZENIO and may cause serious infections that can lead to death. Your healthcare provider should check your white blood cell counts before and during treatment. If you develop low white blood cell counts during treatment with VERZENIO, your healthcare provider may tell you to temporarily stop taking VERZENIO, decrease your dose, or wait before starting your next month of treatment. Tell your healthcare provider right away if you have signs and symptoms of low white blood cell counts or infections, such as fever and chills. Lung problems. VERZENIO may cause severe or life-threatening inflammation of the lungs during treatment that can lead to death. If you develop lung problems during treatment with VERZENIO, your healthcare provider may tell you to temporarily stop taking VERZENIO, decrease your dose, or stop your treatment. Tell your healthcare provider right away if you have any new or worsening symptoms, including: – trouble breathing or shortness of breath – cough with or without mucus – chest pain Liver problems. VERZENIO can cause serious liver problems. Your healthcare provider should do blood tests to check your liver before and during treatment with VERZENIO. If you develop liver problems during treatment with VERZENIO, your healthcare provider may reduce your dose or stop your treatment. Tell your healthcare provider right away if you have any of the following signs and symptoms of liver problems: – feeling very tired – pain on the upper right side of your stomach area (abdomen) – loss of appetite – bleeding or bruising more easily than normal Blood clots in your veins, or in the arteries of your lungs. VERZENIO may cause serious blood clots that have led to death. If you develop blood clots during treatment with VERZENIO, your healthcare provider may tell you to temporarily stop taking VERZENIO. Tell your healthcare provider right away if you get any of the following signs and symptoms of a blood clot: – pain or swelling in your arms or legs – shortness of breath – chest pain – rapid breathing – rapid heart rate See “ What are the possible side effects of VERZENIO? ” for more information about side effects. What is VERZENIO? VERZENIO is a prescription medicine used: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer with a high risk of coming back as determined by your healthcare provider. in combination with an aromatase inhibitor as the first endocrine-based therapy to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has worsened or that has spread to other parts of the body (metastatic). in combination with fulvestrant to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has worsened or spread to other parts of the body (metastatic) and whose disease has progressed after endocrine therapy. alone to treat adults with HR-positive, HER2-negative breast cancer that has worsened or that has spread to other parts of the body (metastatic) and whose disease has progressed after endocrine therapy and prior chemotherapy. When VERZENIO is used in combination with fulvestrant, tamoxifen, or an aromatase inhibitor, also read the Patient Information for the prescribed product. Ask your healthcare provider if you are not sure. It is not known if VERZENIO is safe and effective in children. Before taking VERZENIO, tell your healthcare provider about all of your medical conditions, including if you: have fever, chills, or any other signs of an infection. have a history of blood clots in your veins. have lung or breathing problems. have liver or kidney problems. are pregnant or plan to become pregnant. VERZENIO can harm your unborn baby. Females who are able to become pregnant: – Your healthcare provider will do a pregnancy test before you start treatment with VERZENIO. – You should use effective birth control (contraception) during treatment with VERZENIO and for 3 weeks after the last dose of VERZENIO. – Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with VERZENIO. are breastfeeding or plan to breastfeed. It is not known if VERZENIO passes into your breast milk. Do not breastfeed during treatment with VERZENIO and for at least 3 weeks after the last dose of VERZENIO. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VERZENIO may affect the way other medicines work, and other medicines may affect how VERZENIO works, causing serious side effects. Especially tell your healthcare provider if you take a medicine that contains ketoconazole. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine. How should I take VERZENIO? Take VERZENIO exactly as your healthcare provider tells you. Your healthcare provider may change your dose if needed. Do not stop taking VERZENIO or change the dose without talking to your healthcare provider. VERZENIO may be taken with or without food. Swallow VERZENIO tablets whole. Do not chew, crush, or split the tablets before swallowing. Do not take VERZENIO tablets if they are broken, cracked, or damaged. Take your doses of VERZENIO at about the same time every day. If you vomit or miss a dose of VERZENIO, take your next dose at your regular time. Do not take 2 doses of VERZENIO at the same time to make up for the missed dose. What should I avoid during treatment with VERZENIO? Avoid taking ketoconazole during treatment with VERZENIO. Tell your healthcare provider if you take a medicine that contains ketoconazole. Avoid grapefruit and products that contain grapefruit during treatment with VERZENIO. Grapefruit may increase the amount of VERZENIO in your blood. What are the possible side effects of VERZENIO? VERZENIO may cause serious side effects, including: See “ What is the most important information I should know about VERZENIO? ” The most common side effects of VERZENIO include: nausea infections low red blood cell counts (anemia) decreased appetite headache hair thinning or hair loss (alopecia) abdominal pain tiredness low white blood cell counts (leukopenia) vomiting low platelet count (thrombocytopenia) VERZENIO may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if this is a concern for you. These are not all the possible side effects of VERZENIO. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store VERZENIO? Store VERZENIO at room temperature between 68°F to 77°F (20°C to 25°C). Keep VERZENIO and all medicines out of the reach of children. General information about the safe and effective use of VERZENIO. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VERZENIO for a condition for which it was not prescribed. Do not give VERZENIO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for more information about VERZENIO that is written for health professionals. What are the ingredients in VERZENIO? Active ingredient: abemaciclib Inactive ingredients: microcrystalline cellulose 102, microcrystalline cellulose 101, lactose monohydrate, croscarmellose sodium, sodium stearyl fumarate, silicon dioxide. Color mixture ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide yellow, iron oxide red. Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA Copyright © 2017, 2023, Eli Lilly and Company. All rights reserved. VER-0005-PPI-20230303 For more information, go to www.verzenio.com or call 1-800-545-5979."],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on findings in animals and its mechanism of action, VERZENIO can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus. In animal reproduction studies, administration of abemaciclib during organogenesis was teratogenic and caused decreased fetal weight at maternal exposures that were similar to human clinical exposure based on AUC at the maximum recommended human dose ( see Data). Advise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies. Data Animal Data In an embryo-fetal development study, pregnant rats received oral doses of abemaciclib up to 15 mg/kg/day during the period of organogenesis. Doses ≥4 mg/kg/day caused decreased fetal body weights and increased incidence of cardiovascular and skeletal malformations and variations. These findings included absent innominate artery and aortic arch, malpositioned subclavian artery, unossified sternebra, bipartite ossification of thoracic centrum, and rudimentary or nodulated ribs. At 4 mg/kg/day in rats, the maternal systemic exposures were approximately equal to the human exposure (AUC) at the recommended dose. 8.2 Lactation Risk Summary There are no data on the presence of abemaciclib in human milk, or its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed infants from VERZENIO, advise lactating women not to breastfeed during VERZENIO treatment and for 3 weeks after the last dose. 8.3 Females and Males of Reproductive Potential Based on animal studies, VERZENIO can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1 )] . Pregnancy Testing Verify pregnancy status in females of reproductive potential prior to initiating treatment with VERZENIO. Contraception Females Advise females of reproductive potential to use effective contraception during VERZENIO treatment and for 3 weeks after the last dose. Infertility Males Based on findings in animals, VERZENIO may impair fertility in males of reproductive potential [see Nonclinical Toxicology ( 13.1 )] . 8.4 Pediatric Use The safety and effectiveness of VERZENIO have not been established in pediatric patients. The safety and effectiveness of VERZENIO in combination with chemotherapy was assessed but not established in an open label, dose-finding trial (NCT04238819) in 43 pediatric patients aged 1 to < 17 years with relapsed/refractory solid tumors. No new safety signals were observed in pediatric patients in this study. Abemaciclib exposure in pediatric patients was within the range of the values previously observed in adults given a similar dose per body surface area. 8.5 Geriatric Use Of the 2791 VERZENIO-treated patients in monarchE, 15% were 65 years of age or older and 2.7% were 75 years of age or older. Of the 900 patients who received VERZENIO in MONARCH 1, MONARCH 2, and MONARCH 3, 38% were 65 years of age or older and 10% were 75 years of age or older. The most common adverse reactions (≥5%) Grade 3 or 4 in patients ≥65 years of age across MONARCH 1, 2, and 3 were: neutropenia, diarrhea, fatigue, nausea, dehydration, leukopenia, anemia, infections, and ALT increased. No overall differences in safety or effectiveness of VERZENIO were observed between these patients and younger patients. 8.6 Renal Impairment No dosage adjustment is required for patients with mild or moderate renal impairment (CLcr ≥30-89 mL/min, estimated by Cockcroft-Gault [C-G]). The pharmacokinetics of abemaciclib in patients with severe renal impairment (CLcr <30 mL/min, C-G), end stage renal disease, or in patients on dialysis is unknown [see Clinical Pharmacology ( 12.3 )] . 8.7 Hepatic Impairment No dosage adjustments are necessary in patients with mild or moderate hepatic impairment (Child-Pugh A or B). Reduce the dosing frequency when administering VERZENIO to patients with severe hepatic impairment (Child-Pugh C) [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )] ."],"dosage_and_administration_table":["
Table 1: VERZENIO Dose Modification — Adverse Reactions
Dose LevelVERZENIO Dose Combination with Fulvestrant, Tamoxifen, or an Aromatase InhibitorVERZENIO Dose for Monotherapy
Recommended starting dose 150 mg twice daily 200 mg twice daily
First dose reduction 100 mg twice daily 150 mg twice daily
Second dose reduction 50 mg twice daily 100 mg twice daily
Third dose reduction not applicable 50 mg twice daily
","
Table 2: VERZENIO Dose Modification and Management — Hematologic Toxicitiesa
Abbreviation: CTCAE = Common Terminology Criteria for Adverse Events.
a If blood cell growth factors are required, suspend VERZENIO dose for at least 48 hours after the last dose of blood cell growth factor and until toxicity resolves to ≤Grade 2. Resume at next lower dose unless already performed for the toxicity that led to the use of the growth factor. Growth factor use as per current treatment guidelines.
Monitor complete blood counts prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.
CTCAE GradeVERZENIO Dose Modifications
Grade 1 or 2 No dose modification is required.
Grade 3 Suspend dose until toxicity resolves to ≤Grade 2. Dose reduction is not required.
Grade 3 recurrent, or Grade 4 Suspend dose until toxicity resolves to ≤Grade 2. Resume at next lower dose.
","
Table 3: VERZENIO Dose Modification and Management — Diarrhea
At the first sign of loose stools, start treatment with antidiarrheal agents and increase intake of oral fluids.
CTCAE GradeVERZENIO Dose Modifications
Grade 1 No dose modification is required.
Grade 2 If toxicity does not resolve within 24 hours to ≤Grade 1, suspend dose until resolution. No dose reduction is required.
Grade 2 that persists or recurs after resuming the same dose despite maximal supportive measures Suspend dose until toxicity resolves to ≤Grade 1. Resume at next lower dose.
Grade 3 or 4 or requires hospitalization Suspend dose until toxicity resolves to ≤Grade 1. Resume at next lower dose.
","
Table 4: VERZENIO Dose Modification and Management — Hepatotoxicity
Abbreviations: ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN = upper limit of normal.
Monitor ALT, AST, and serum bilirubin prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.
CTCAE Grade for ALT and ASTVERZENIO Dose Modifications
Grade 1 (>ULN-3.0 x ULN) Grade 2 (>3.0-5.0 x ULN), WITHOUT increase in total bilirubin above 2 x ULN No dose modification is required.
Persistent or Recurrent Grade 2, or Grade 3 (>5.0-20.0 x ULN), WITHOUT increase in total bilirubin above 2 x ULN Suspend dose until toxicity resolves to baseline or Grade 1. Resume at next lower dose.
Elevation in AST and/or ALT >3 x ULN WITH total bilirubin >2 x ULN, in the absence of cholestasis Discontinue VERZENIO.
Grade 4 (>20.0 x ULN) Discontinue VERZENIO.
","
Table 5: VERZENIO Dose Modification and Management — Interstitial Lung Disease/Pneumonitis
CTCAE GradeVERZENIO Dose Modifications
Grade 1 or 2 No dose modification is required.
Persistent or recurrent Grade 2 toxicity that does not resolve with maximal supportive measures within 7 days to baseline or Grade 1 Suspend dose until toxicity resolves to baseline or ≤Grade 1. Resume at next lower dose.
Grade 3 or 4 Discontinue VERZENIO.
","
Table 6: VERZENIO Dose Modification and Management — Venous Thromboembolic Events (VTEs)
CTCAE GradeVERZENIO Dose Modifications
Early Breast Cancer
Any Grade Suspend dose and treat as clinically indicated. Resume VERZENIO when the patient is clinically stable.
Advanced or Metastatic Breast Cancer
Grade 1 or 2 No dose modification is required.
Grade 3 or 4 Suspend dose and treat as clinically indicated. Resume VERZENIO when the patient is clinically stable.
","
Table 7: VERZENIO Dose Modification and Management — Other Toxicitiesa
a Excluding diarrhea, hematologic toxicity, hepatotoxicity, ILD/pneumonitis, and VTEs.
CTCAE GradeVERZENIO Dose Modifications
Grade 1 or 2 No dose modification is required.
Persistent or recurrent Grade 2 toxicity that does not resolve with maximal supportive measures within 7 days to baseline or Grade 1 Suspend dose until toxicity resolves to baseline or ≤Grade 1. Resume at next lower dose.
Grade 3 or 4 Suspend dose until toxicity resolves to baseline or ≤Grade 1. Resume at next lower dose.
"],"spl_patient_package_insert_table":["If you have any loose stools, start taking an antidiarrheal medicine (such as loperamide), drink more fluids, and tell your healthcare provider right away. Low white blood cell counts (neutropenia). Low white blood cell counts are common during treatment with VERZENIO and may cause serious infections that can lead to death. Your healthcare provider should check your white blood cell counts before and during treatment. If you develop low white blood cell counts during treatment with VERZENIO, your healthcare provider may tell you to temporarily stop taking VERZENIO, decrease your dose, or wait before starting your next month of treatment. Tell your healthcare provider right away if you have signs and symptoms of low white blood cell counts or infections, such as fever and chills.Lung problems. VERZENIO may cause severe or life-threatening inflammation of the lungs during treatment that can lead to death. If you develop lung problems during treatment with VERZENIO, your healthcare provider may tell you to temporarily stop taking VERZENIO, decrease your dose, or stop your treatment. Tell your healthcare provider right away if you have any new or worsening symptoms, including:trouble breathing or shortness of breath cough with or without mucus chest pain Liver problems. VERZENIO can cause serious liver problems. Your healthcare provider should do blood tests to check your liver before and during treatment with VERZENIO. If you develop liver problems during treatment with VERZENIO, your healthcare provider may reduce your dose or stop your treatment. Tell your healthcare provider right away if you have any of the following signs and symptoms of liver problems: feeling very tired pain on the upper right side of your stomach area (abdomen) loss of appetite bleeding or bruising more easily than normal pain or swelling in your arms or legs shortness of breath chest pain rapid breathing rapid heart rate Your healthcare provider will do a pregnancy test before you start treatment with VERZENIO. You should use effective birth control (contraception) during treatment with VERZENIO and for 3 weeks after the last dose of VERZENIO. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with VERZENIO. are breastfeeding or plan to breastfeed. It is not known if VERZENIO passes into your breast milk. Do not breastfeed during treatment with VERZENIO and for at least 3 weeks after the last dose of VERZENIO.
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: March-2023
PATIENT INFORMATION VERZENIO® (ver-ZEN-ee-oh) (abemaciclib) tablets
What is the most important information I should know about VERZENIO? VERZENIO may cause serious side effects including: Diarrhea. Diarrhea is common with VERZENIO treatment and may sometimes be severe. Diarrhea may cause you to develop dehydration or an infection. The most common time to develop diarrhea is during the first month of VERZENIO treatment. If you develop diarrhea during treatment with VERZENIO, your healthcare provider may tell you to temporarily stop taking VERZENIO, stop your treatment, or decrease your dose.
– – – –
– –
– –
Blood clots in your veins, or in the arteries of your lungs. VERZENIO may cause serious blood clots that have led to death. If you develop blood clots during treatment with VERZENIO, your healthcare provider may tell you to temporarily stop taking VERZENIO. Tell your healthcare provider right away if you get any of the following signs and symptoms of a blood clot:
– – –
– –
See “What are the possible side effects of VERZENIO?” for more information about side effects.
What is VERZENIO? VERZENIO is a prescription medicine used: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer with a high risk of coming back as determined by your healthcare provider. in combination with an aromatase inhibitor as the first endocrine-based therapy to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has worsened or that has spread to other parts of the body (metastatic). in combination with fulvestrant to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has worsened or spread to other parts of the body (metastatic) and whose disease has progressed after endocrine therapy. alone to treat adults with HR-positive, HER2-negative breast cancer that has worsened or that has spread to other parts of the body (metastatic) and whose disease has progressed after endocrine therapy and prior chemotherapy.
When VERZENIO is used in combination with fulvestrant, tamoxifen, or an aromatase inhibitor, also read the Patient Information for the prescribed product. Ask your healthcare provider if you are not sure. It is not known if VERZENIO is safe and effective in children.
Before taking VERZENIO, tell your healthcare provider about all of your medical conditions, including if you: have fever, chills, or any other signs of an infection. have a history of blood clots in your veins. have lung or breathing problems. have liver or kidney problems. are pregnant or plan to become pregnant. VERZENIO can harm your unborn baby. Females who are able to become pregnant:
– – –
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VERZENIO may affect the way other medicines work, and other medicines may affect how VERZENIO works, causing serious side effects. Especially tell your healthcare provider if you take a medicine that contains ketoconazole. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.
How should I take VERZENIO? Take VERZENIO exactly as your healthcare provider tells you. Your healthcare provider may change your dose if needed. Do not stop taking VERZENIO or change the dose without talking to your healthcare provider. VERZENIO may be taken with or without food. Swallow VERZENIO tablets whole. Do not chew, crush, or split the tablets before swallowing. Do not take VERZENIO tablets if they are broken, cracked, or damaged. Take your doses of VERZENIO at about the same time every day. If you vomit or miss a dose of VERZENIO, take your next dose at your regular time. Do not take 2 doses of VERZENIO at the same time to make up for the missed dose.
What should I avoid during treatment with VERZENIO? Avoid taking ketoconazole during treatment with VERZENIO. Tell your healthcare provider if you take a medicine that contains ketoconazole. Avoid grapefruit and products that contain grapefruit during treatment with VERZENIO. Grapefruit may increase the amount of VERZENIO in your blood.
What are the possible side effects of VERZENIO? VERZENIO may cause serious side effects, including: See “What is the most important information I should know about VERZENIO?”
The most common side effects of VERZENIO include:
nausea infections low red blood cell counts (anemia) decreased appetite headache hair thinning or hair loss (alopecia) abdominal pain tiredness low white blood cell counts (leukopenia) vomiting low platelet count (thrombocytopenia)
VERZENIO may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if this is a concern for you. These are not all the possible side effects of VERZENIO. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store VERZENIO? Store VERZENIO at room temperature between 68°F to 77°F (20°C to 25°C).
Keep VERZENIO and all medicines out of the reach of children.
General information about the safe and effective use of VERZENIO. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VERZENIO for a condition for which it was not prescribed. Do not give VERZENIO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for more information about VERZENIO that is written for health professionals.
What are the ingredients in VERZENIO? Active ingredient: abemaciclib Inactive ingredients: microcrystalline cellulose 102, microcrystalline cellulose 101, lactose monohydrate, croscarmellose sodium, sodium stearyl fumarate, silicon dioxide. Color mixture ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide yellow, iron oxide red. Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA Copyright © 2017, 2023, Eli Lilly and Company. All rights reserved. VER-0005-PPI-20230303 For more information, go to www.verzenio.com or call 1-800-545-5979.
"],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology In repeat-dose toxicity studies up to 6-months duration, oral administration of abemaciclib resulted in retinal atrophy of the eyes in mice at a dose of 150 mg/kg/day (approximately 10 times the exposure at the maximum recommended human dose based on AUC) and in rats at a dose of 30 mg/kg/day (approximately 5 times the exposure at the maximum recommended human dose based on AUC). In a 2-year rat carcinogenicity study, oral administration of abemaciclib resulted in retinal atrophy in the eyes at doses ≥0.3 mg/kg/day (approximately 0.05 times the exposure at the maximum recommended human dose based on AUC)."],"package_label_principal_display_panel":["PACKAGE CARTON – VERZENIO 50 mg 14ct 14 tablets NDC 0002-4483-54 Rx only Verzenio ® (abemaciclib) tablets 50 mg dose 7-Day Supply This 50 mg Dose Pack contains fourteen 50 mg tablets. www.verzenio.com LIFT TO OPEN Lilly PACKAGE CARTON – VERZENIO 50 mg 14ct PACKAGE CARTON – VERZENIO 50 mg 14ct","PACKAGE CARTON – VERZENIO 100 mg 14ct 14 tablets NDC 0002-4815-54 Rx only Verzenio ® (abemaciclib) tablets 100 mg dose 7-Day Supply This 100 mg Dose Pack contains fourteen 100 mg tablets. www.verzenio.com LIFT TO OPEN Lilly PACKAGE CARTON – VERZENIO 100 mg 14ct PACKAGE CARTON – VERZENIO 100 mg 14ct","PACKAGE CARTON – VERZENIO 150 mg 14ct 14 tablets NDC 0002-5337-54 Rx only Verzenio ® (abemaciclib) tablets 150 mg dose 7-Day Supply This 150 mg Dose Pack contains fourteen 150 mg tablets. www.verzenio.com LIFT TO OPEN Lilly PACKAGE CARTON – VERZENIO 150 mg 14ct PACKAGE CARTON – VERZENIO 150 mg 14ct","PACKAGE CARTON – VERZENIO 200 mg 14ct 14 tablets NDC 0002-6216-54 Rx only Verzenio ® (abemaciclib) tablets 200 mg dose 7-Day Supply This 200 mg Dose Pack contains fourteen 200 mg tablets. www.verzenio.com LIFT TO OPEN Lilly PACKAGE CARTON – VERZENIO 200 mg 14ct PACKAGE CARTON – VERZENIO 200 mg 14ct"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Abemaciclib was assessed for carcinogenicity in a 2-year rat study. Abemaciclib was not carcinogenic in male and female rats at oral doses up to 3 mg/kg/day (approximately 1 time the exposure at the maximum recommended human dose based on AUC). Abemaciclib and its active human metabolites M2 and M20 were not mutagenic in a bacterial reverse mutation (Ames) assay or clastogenic in an in vitro chromosomal aberration assay in Chinese hamster ovary cells or human peripheral blood lymphocytes. Abemaciclib, M2, and M20 were not clastogenic in an in vivo rat bone marrow micronucleus assay. Abemaciclib may impair fertility in males of reproductive potential. In repeat-dose toxicity studies up to 3-months duration, abemaciclib-related findings in the testis, epididymis, prostate, and seminal vesicle at doses ≥10 mg/kg/day in rats and ≥0.3 mg/kg/day in dogs included decreased organ weights, intratubular cellular debris, hypospermia, tubular dilatation, atrophy, and degeneration/necrosis. These doses in rats and dogs resulted in approximately 2 and 0.02 times, respectively, the exposure (AUC) in humans at the maximum recommended human dose. In a rat male fertility study, abemaciclib had no effects on mating and fertility at oral doses up to 10 mg/kg/day (approximately 2 times the exposure at the maximum recommended human dose based on AUC). In a rat female fertility and early embryonic development study, abemaciclib did not affect mating and fertility at doses up to 20 mg/kg/day (approximately 3 times the exposure at the maximum recommended human dose based on AUC)."]},"tags":[{"label":"Kinase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Cyclin-dependent kinase 4","category":"target"},{"label":"CDK4","category":"gene"},{"label":"CDK6","category":"gene"},{"label":"CLK1","category":"gene"},{"label":"L01EF03","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Hormone receptor positive malignant neoplasm of breast","category":"indication"},{"label":"Human epidermal growth factor 2 negative carcinoma of breast","category":"indication"},{"label":"Eli Lilly And Co","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"5308 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"2109 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"1819 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"1006 reports"},{"date":"","signal":"MALIGNANT NEOPLASM PROGRESSION","source":"FDA FAERS","actionTaken":"979 reports"},{"date":"","signal":"DECREASED APPETITE","source":"FDA FAERS","actionTaken":"820 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"737 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"734 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"697 reports"},{"date":"","signal":"WHITE BLOOD CELL COUNT DECREASED","source":"FDA FAERS","actionTaken":"620 reports"}],"drugInteractions":[{"drug":"Ketoconazole","severity":"High","mechanism":"Strong CYP3A4 inhibitor","management":"Avoid concomitant use","clinicalEffect":"Predicted to increase AUC of abemaciclib up to 16-fold"},{"drug":"Other strong CYP3A inhibitors","severity":"High","mechanism":"CYP3A4 inhibition increases abemaciclib exposure","management":"Reduce VERZENIO dose to 100 mg twice daily (from 200 mg or 150 mg twice daily); further reduce to 50 mg twice daily if already at 100 mg twice daily due to adverse reactions; increase dose after 3-5 half-lives of inhibitor discontinuation","clinicalEffect":"Increased toxicity"},{"drug":"Moderate CYP3A inhibitors","severity":"Moderate","mechanism":"CYP3A4 inhibition increases abemaciclib exposure","management":"Monitor for adverse reactions; consider reducing VERZENIO dose in 50 mg decrements if necessary","clinicalEffect":"Increased adverse reactions"},{"drug":"Strong and moderate CYP3A inducers","severity":"High","mechanism":"CYP3A4 induction decreases abemaciclib plasma concentrations","management":"Avoid concomitant use; consider alternative agents","clinicalEffect":"Reduced activity"},{"drug":"Grapefruit products","severity":"Moderate","mechanism":"CYP3A4 inhibition","management":"Avoid grapefruit products","clinicalEffect":"Increased abemaciclib exposure"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"53.1%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":311,"totalAffected":165,"trialsReporting":9},{"effect":"Diarrhoea","drugRate":"53.3%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":270,"totalAffected":144,"trialsReporting":6},{"effect":"Fatigue","drugRate":"46.0%","organSystem":"General disorders and administration site conditions","placeboRate":"","totalAtRisk":211,"totalAffected":97,"trialsReporting":8},{"effect":"Asthenia","drugRate":"35.4%","organSystem":"General disorders","placeboRate":"","totalAtRisk":263,"totalAffected":93,"trialsReporting":5},{"effect":"Alopecia","drugRate":"30.3%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":284,"totalAffected":86,"trialsReporting":8},{"effect":"Vomiting","drugRate":"26.4%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":311,"totalAffected":82,"trialsReporting":9},{"effect":"Decreased appetite","drugRate":"27.0%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":267,"totalAffected":72,"trialsReporting":5},{"effect":"Constipation","drugRate":"20.9%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":311,"totalAffected":65,"trialsReporting":9},{"effect":"Abdominal pain","drugRate":"19.8%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":308,"totalAffected":61,"trialsReporting":8},{"effect":"Neutrophil count decreased","drugRate":"25.7%","organSystem":"Investigations","placeboRate":"","totalAtRisk":210,"totalAffected":54,"trialsReporting":7},{"effect":"Headache","drugRate":"16.1%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":311,"totalAffected":50,"trialsReporting":9},{"effect":"Neutropenia","drugRate":"16.7%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":270,"totalAffected":45,"trialsReporting":6},{"effect":"Cough","drugRate":"14.1%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":311,"totalAffected":44,"trialsReporting":9},{"effect":"Anaemia","drugRate":"24.7%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":170,"totalAffected":42,"trialsReporting":5},{"effect":"Dysgeusia","drugRate":"12.5%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":311,"totalAffected":39,"trialsReporting":9},{"effect":"Arthralgia","drugRate":"12.7%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":284,"totalAffected":36,"trialsReporting":8},{"effect":"Back pain","drugRate":"11.4%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":308,"totalAffected":35,"trialsReporting":8},{"effect":"Platelet count decreased","drugRate":"16.2%","organSystem":"Investigations","placeboRate":"","totalAtRisk":210,"totalAffected":34,"trialsReporting":7},{"effect":"Diarrhea","drugRate":"64.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":50,"totalAffected":32,"trialsReporting":4},{"effect":"Dyspepsia","drugRate":"8.6%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":304,"totalAffected":26,"trialsReporting":8},{"effect":"Pain","drugRate":"11.8%","organSystem":"General disorders and administration site conditions","placeboRate":"","totalAtRisk":211,"totalAffected":25,"trialsReporting":8},{"effect":"Dizziness","drugRate":"11.8%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":211,"totalAffected":25,"trialsReporting":8},{"effect":"Mucosal inflammation","drugRate":"18.8%","organSystem":"General disorders","placeboRate":"","totalAtRisk":128,"totalAffected":24,"trialsReporting":3},{"effect":"White blood cell count decreased","drugRate":"15.0%","organSystem":"Investigations","placeboRate":"","totalAtRisk":160,"totalAffected":24,"trialsReporting":3},{"effect":"Stomatitis","drugRate":"8.4%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":263,"totalAffected":22,"trialsReporting":5},{"effect":"Weight decreased","drugRate":"12.6%","organSystem":"Investigations","placeboRate":"","totalAtRisk":167,"totalAffected":21,"trialsReporting":4},{"effect":"Anemia","drugRate":"42.0%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":50,"totalAffected":21,"trialsReporting":4},{"effect":"Pruritus","drugRate":"7.2%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":277,"totalAffected":20,"trialsReporting":7},{"effect":"Dyspnoea","drugRate":"11.2%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":170,"totalAffected":19,"trialsReporting":5},{"effect":"Neurotoxicity","drugRate":"16.7%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":108,"totalAffected":18,"trialsReporting":2},{"effect":"Abdominal pain upper","drugRate":"11.2%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":160,"totalAffected":18,"trialsReporting":3},{"effect":"Dry mouth","drugRate":"10.3%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":174,"totalAffected":18,"trialsReporting":5},{"effect":"Pyrexia","drugRate":"10.6%","organSystem":"General disorders","placeboRate":"","totalAtRisk":170,"totalAffected":18,"trialsReporting":5},{"effect":"Aspartate aminotransferase increased","drugRate":"10.3%","organSystem":"Investigations","placeboRate":"","totalAtRisk":174,"totalAffected":18,"trialsReporting":5},{"effect":"Alanine aminotransferase increased","drugRate":"9.3%","organSystem":"Investigations","placeboRate":"","totalAtRisk":183,"totalAffected":17,"trialsReporting":6},{"effect":"Blood creatinine increased","drugRate":"10.2%","organSystem":"Investigations","placeboRate":"","totalAtRisk":167,"totalAffected":17,"trialsReporting":4},{"effect":"Thrombocytopenia","drugRate":"9.6%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":167,"totalAffected":16,"trialsReporting":4},{"effect":"Oedema peripheral","drugRate":"9.6%","organSystem":"General disorders","placeboRate":"","totalAtRisk":167,"totalAffected":16,"trialsReporting":4},{"effect":"Peripheral sensory neuropathy","drugRate":"9.3%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":161,"totalAffected":15,"trialsReporting":5},{"effect":"Myalgia","drugRate":"5.4%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":277,"totalAffected":15,"trialsReporting":7},{"effect":"Insomnia","drugRate":"9.9%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":152,"totalAffected":15,"trialsReporting":7},{"effect":"Urinary tract infection","drugRate":"5.5%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":274,"totalAffected":15,"trialsReporting":6},{"effect":"Dehydration","drugRate":"7.2%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":208,"totalAffected":15,"trialsReporting":7},{"effect":"Anxiety","drugRate":"7.5%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":201,"totalAffected":15,"trialsReporting":6},{"effect":"Paraesthesia","drugRate":"11.4%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":123,"totalAffected":14,"trialsReporting":3},{"effect":"Hypokalaemia","drugRate":"8.4%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":167,"totalAffected":14,"trialsReporting":4},{"effect":"Anorexia","drugRate":"34.1%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":41,"totalAffected":14,"trialsReporting":3},{"effect":"Flatulence","drugRate":"7.6%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":170,"totalAffected":13,"trialsReporting":4},{"effect":"Dry skin","drugRate":"7.2%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":167,"totalAffected":12,"trialsReporting":4},{"effect":"Upper respiratory tract infection","drugRate":"6.6%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":167,"totalAffected":11,"trialsReporting":4}],"specialPopulations":{"Lactation":"There are no data on the presence of abemaciclib in human milk, or its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed infants from VERZENIO, advise lactating women not to breastfeed during VERZENIO treatment and for weeks after the last dose.","Pregnancy":"Based on findings in animals and its mechanism of action, VERZENIO can cause fetal harm when administered to pregnant woman. There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to fetus. In animal reproduction studies, administration of abemaciclib during organogenesis was teratogenic and caused decreased fetal weight at maternal exposures that were similar to human clinical exposure based on AUC at the maximum recommended human dose.","Geriatric use":"Of the 2791 VERZENIO-treated patients in monarchE, 15% were 65 years of age or older and 2.7% were 75 years of age or older. Of the 900 patients who received VERZENIO in MONARCH 1, MONARCH 2, and MONARCH 3, 38% were 65 years of age or older and 10% were 75 years of age or older. The most common adverse reactions (>=5%) Grade or in patients >=65 years of age across MONARCH 1, 2, and were: neutropenia, diarrhea, fatigue, nausea, dehydration, leukopenia, anemia, infections, and AL","Paediatric use":"The safety and effectiveness of VERZENIO have not been established in pediatric patients."},"seriousAdverseEvents":[{"event":"Anemia","detail":"Blood and lymphatic system disorders. 2 trial(s).","severity":"serious","incidence":"8.8%"},{"event":"Hypokalemia","detail":"Metabolism and nutrition disorders. 2 trial(s).","severity":"serious","incidence":"8.3%"},{"event":"Diarrhea","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"7.4%"},{"event":"Platelet count decreased","detail":"Investigations. 3 trial(s).","severity":"serious","incidence":"7.1%"},{"event":"Stroke","detail":"Nervous system disorders. 2 trial(s).","severity":"serious","incidence":"6.2%"},{"event":"Gait disturbance","detail":"General disorders. 2 trial(s).","severity":"serious","incidence":"5.6%"},{"event":"Sinus tachycardia","detail":"Cardiac disorders. 2 trial(s).","severity":"serious","incidence":"5.6%"},{"event":"Generalized muscle weakness","detail":"Musculoskeletal and connective tissue disorders. 2 trial(s).","severity":"serious","incidence":"5.6%"},{"event":"Leukocytosis","detail":"Blood and lymphatic system disorders. 1 trial(s).","severity":"serious","incidence":"5.0%"},{"event":"Tumour pain","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"5.0%"},{"event":"Neuropathy peripheral","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"5.0%"},{"event":"Nausea","detail":"Gastrointestinal disorders. 5 trial(s).","severity":"serious","incidence":"4.5%"},{"event":"Fatigue","detail":"General disorders. 4 trial(s).","severity":"serious","incidence":"4.4%"},{"event":"Pericardial effusion","detail":"Cardiac disorders. 2 trial(s).","severity":"serious","incidence":"4.3%"},{"event":"Vomiting","detail":"Gastrointestinal disorders. 6 trial(s).","severity":"serious","incidence":"3.8%"},{"event":"Bloating","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"3.7%"},{"event":"Colonic obstruction","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"3.7%"},{"event":"Cough","detail":"Respiratory, thoracic and mediastinal disorders. 1 trial(s).","severity":"serious","incidence":"3.7%"},{"event":"Respiratory failure","detail":"Respiratory, thoracic and mediastinal disorders. 1 trial(s).","severity":"serious","incidence":"3.7%"},{"event":"Anorexia","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"3.7%"},{"event":"Chest pain-cardiac","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"3.7%"},{"event":"Pain","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"3.7%"},{"event":"Dizziness","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"3.7%"},{"event":"Diarrhoea","detail":"Gastrointestinal disorders. 3 trial(s).","severity":"serious","incidence":"2.9%"},{"event":"Presyncope","detail":"Nervous system disorders. 5 trial(s).","severity":"serious","incidence":"2.9%"},{"event":"Dehydration","detail":"Metabolism and nutrition disorders. 4 trial(s).","severity":"serious","incidence":"2.9%"},{"event":"Hypoxia","detail":"Respiratory, thoracic and mediastinal disorders. 2 trial(s).","severity":"serious","incidence":"2.9%"},{"event":"Blood bilirubin increased","detail":"Investigations. 2 trial(s).","severity":"serious","incidence":"2.9%"},{"event":"Depression","detail":"Psychiatric disorders. 2 trial(s).","severity":"serious","incidence":"2.9%"},{"event":"Headache","detail":"Nervous system disorders. 3 trial(s).","severity":"serious","incidence":"2.8%"}]},"trials":[],"aliases":[],"company":"Eli Lilly","patents":[{"applNo":"N208716","source":"FDA Orange Book","status":"Active","expires":"Sep 28, 2031","useCode":"U-2135","territory":"US","drugProduct":true,"patentNumber":"7855211","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=abemaciclib","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:41:10.477782+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:41:04.191131+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Abemaciclib","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:41:19.647999+00:00"},"mechanism":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:33:50.321649+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:41:17.735958+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:41:10.497097+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:41:02.789776+00:00"},"pharmacokinetics":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:33:50.321674+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=abemaciclib","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:41:19.025784+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:41:01.710440+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:41:01.710451+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:41:01.710454+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:41:20.699946+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Cyclin-dependent kinase 6 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:41:19.647653+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3301610/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:41:19.539870+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (10 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T08:33:50.881124+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA208716","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:41:01.710456+00:00"}},"allNames":"verzenio","offLabel":[],"synonyms":["abemaciclib","LY2835219","verzenio"],"timeline":[{"date":"2017-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ELI LILLY AND CO to Eli Lilly And Co"},{"date":"2017-09-28","type":"positive","source":"DrugCentral","milestone":"FDA approval (Eli Lilly And Co)"},{"date":"2018-09-21","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Eli Lilly Japan KK)"},{"date":"2031-09-28","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 7855211 expires"}],"aiSummary":"Abemaciclib is a CDK4/6 inhibitor indicated for HR+/HER2- breast cancer in combination with endocrine therapy or as monotherapy. It demonstrates strong protein binding (>93%) and hepatic metabolism via CYP3A4 with an 18.3-hour half-life, requiring dose adjustments with CYP3A inhibitors. The drug carries significant drug interaction risks, particularly with ketoconazole and other CYP3A inhibitors, necessitating careful monitoring and dose management. Clinical efficacy is established across early, advanced, and metastatic HR+/HER2- breast cancer settings.","brandName":"Verzenio","ecosystem":[{"indication":"Hormone receptor positive malignant neoplasm of breast","otherDrugs":[{"name":"anastrozole","slug":"anastrozole","company":"Astrazeneca"},{"name":"everolimus","slug":"everolimus","company":"Novartis"},{"name":"exemestane","slug":"exemestane","company":"Pharmacia And Upjohn"},{"name":"fluoxymesterone","slug":"fluoxymesterone","company":""}],"globalPrevalence":null},{"indication":"Human epidermal growth factor 2 negative carcinoma of breast","otherDrugs":[{"name":"olaparib","slug":"olaparib","company":"Astrazeneca Pharms"},{"name":"palbociclib","slug":"palbociclib","company":"Pfizer Inc"}],"globalPrevalence":null}],"mechanism":{"target":"Cyclin-dependent kinases 4 and 6 (CDK4/CDK6)","novelty":"Follow-on","targets":[{"gene":"CDK4","source":"DrugCentral","target":"Cyclin-dependent kinase 4","protein":"Cyclin-dependent kinase 4"},{"gene":"CDK6","source":"DrugCentral","target":"Cyclin-dependent kinase 6","protein":"Cyclin-dependent kinase 6"},{"gene":"CLK1","source":"DrugCentral","target":"Dual specificity protein kinase CLK1","protein":"Dual specificity protein kinase CLK1"},{"gene":"PIM1","source":"DrugCentral","target":"Serine/threonine-protein kinase pim-1","protein":"Serine/threonine-protein kinase pim-1"},{"gene":"CLK4","source":"DrugCentral","target":"Dual specificity protein kinase CLK4","protein":"Dual specificity protein kinase CLK4"},{"gene":"GSK3A","source":"DrugCentral","target":"Glycogen synthase kinase-3 alpha","protein":"Glycogen synthase kinase-3 alpha"},{"gene":"GSK3B","source":"DrugCentral","target":"Glycogen synthase kinase-3 beta","protein":"Glycogen synthase kinase-3 beta"},{"gene":"CAMK2G","source":"DrugCentral","target":"Calcium/calmodulin-dependent protein kinase type II subunit gamma","protein":"Calcium/calmodulin-dependent protein kinase type II subunit gamma"},{"gene":"CAMK2D","source":"DrugCentral","target":"Calcium/calmodulin-dependent protein kinase type II subunit delta","protein":"Calcium/calmodulin-dependent protein kinase type II subunit delta"},{"gene":"CSNK2A2","source":"DrugCentral","target":"Casein kinase II subunit alpha'","protein":"Casein kinase II subunit alpha'"}],"moaClass":"Kinase Inhibitors","modality":"Small molecule","drugClass":"Kinase inhibitor","explanation":"Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which are activated upon binding to D-cyclins. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation. In vitro, continuous exposure to abemaciclib inhibited Rb phosphorylation and blocked progression from G1 into S phase of the cell cycle, resulting in senescence and apoptosis. In breast cancer xenograft models, abemaciclib dosed daily without interruption as a single agent or in combination with antiestrogens resulted in reduction of tumor size.","oneSentence":"Abemaciclib inhibits CDK4 and CDK6, blocking Rb phosphorylation and G1/S cell cycle progression.","technicalDetail":"Verzenio (abemaciclib) is a selective inhibitor of cyclin-dependent kinase 4 (CDK4), which is a critical regulator of the G1/S phase transition in the cell cycle. By blocking CDK4, Verzenio prevents the phosphorylation and activation of the retinoblastoma protein (Rb), leading to cell cycle arrest and apoptosis in cancer cells."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Abemaciclib","title":"Abemaciclib","extract":"Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6."},"commercial":{"launchDate":"2017","revenueYear":2024,"_launchSource":"DrugCentral (FDA 2017-09-28, ELI LILLY AND CO)","annualRevenue":3700,"revenueSource":"Verified: Eli Lilly 10-K","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5259","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=abemaciclib","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=abemaciclib","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Abemaciclib","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T07:26:40.417279","_validation":{"fieldsValidated":9,"lastValidatedAt":"2026-04-20T08:33:52.036709+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"palbociclib","drugSlug":"palbociclib","fdaApproval":"2015-02-03","patentExpiry":"Sep 5, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ribociclib","drugSlug":"ribociclib","fdaApproval":"2017-03-13","patentExpiry":"Nov 9, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"abemaciclib","indications":{"approved":[{"name":"Hormone receptor positive malignant neoplasm of breast","source":"DrugCentral","snomedId":417181009,"regulator":"FDA"},{"name":"Human epidermal growth factor 2 negative carcinoma of breast","source":"DrugCentral","snomedId":431396003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Eli Lilly And Co","drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"palbociclib","brandName":"palbociclib","genericName":"palbociclib","approvalYear":"2015","relationship":"same-class"},{"drugId":"ribociclib","brandName":"ribociclib","genericName":"ribociclib","approvalYear":"2017","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02102490","phase":"PHASE2","title":"A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":true,"startDate":"2014-06-10","conditions":["Metastatic Breast Cancer"],"enrollment":132,"completionDate":"2018-10-22"},{"nctId":"NCT02107703","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","isPivotal":true,"startDate":"2014-07-22","conditions":["Breast Neoplasms"],"enrollment":669,"completionDate":"2027-12"},{"nctId":"NCT03155997","phase":"PHASE3","title":"Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","isPivotal":true,"startDate":"2017-07-12","conditions":["Breast Cancer"],"enrollment":5637,"completionDate":"2029-05"},{"nctId":"NCT05372640","phase":"PHASE1","title":"Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":["Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic NUT Carcinoma","Unresectable Breast Carcinoma","Unresectable Malignant Solid Neoplasm","Unresectable NUT Carcinoma"],"enrollment":45,"completionDate":"2026-06-01"},{"nctId":"NCT06498648","phase":"PHASE1,PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-18","conditions":["Advanced Dedifferentiated Liposarcoma","Advanced Leiomyosarcoma","Advanced Soft Tissue Sarcoma","Metastatic Dedifferentiated Liposarcoma","Metastatic Leiomyosarcoma","Metastatic Soft Tissue Sarcoma","Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8"],"enrollment":74,"completionDate":"2027-01-31"},{"nctId":"NCT06654037","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-04-18","conditions":["Metastatic Microsatellite Stable Colorectal Carcinoma","Refractory Microsatellite Stable Colorectal Carcinoma","Stage IV Colorectal Cancer AJCC v8"],"enrollment":39,"completionDate":"2026-04-01"},{"nctId":"NCT05307705","phase":"PHASE1","title":"A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-05-11","conditions":["Breast Cancer"],"enrollment":193,"completionDate":"2026-12"},{"nctId":"NCT05999994","phase":"PHASE2","title":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-01-22","conditions":["Neoplasms","Child","Adolescent"],"enrollment":105,"completionDate":"2027-05"},{"nctId":"NCT04633239","phase":"PHASE1","title":"Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-07-02","conditions":["Recurrent Ovarian High Grade Serous Adenocarcinoma","Recurrent Platinum-Resistant Ovarian Carcinoma"],"enrollment":42,"completionDate":"2026-11-01"},{"nctId":"NCT07492641","phase":"PHASE3","title":"BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease","status":"NOT_YET_RECRUITING","sponsor":"BeOne Medicines","startDate":"2026-05-11","conditions":["HR+/HER2- Breast Cancer"],"enrollment":1056,"completionDate":"2037-08-07"},{"nctId":"NCT07490509","phase":"PHASE4","title":"Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2026-04","conditions":["Abemaciclib","Abemaciclib-related Diarrhea","Breast Cancer"],"enrollment":235,"completionDate":"2029-04"},{"nctId":"NCT07491380","phase":"NA","title":"Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME)","status":"NOT_YET_RECRUITING","sponsor":"Institut Curie","startDate":"2026-05-15","conditions":["Breast Cancer"],"enrollment":90,"completionDate":"2028-12-15"},{"nctId":"NCT05413304","phase":"PHASE1","title":"Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":["Glioma"],"enrollment":1,"completionDate":"2027-09-01"},{"nctId":"NCT06413706","phase":"PHASE2","title":"A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-25","conditions":["Glioma"],"enrollment":45,"completionDate":"2028-02"},{"nctId":"NCT07487129","phase":"PHASE4","title":"Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-08-25","conditions":["Breast Cancer"],"enrollment":206,"completionDate":"2025-12-20"},{"nctId":"NCT07114601","phase":"PHASE1","title":"A Study of LY4257496 in Participants With Cancer (OMNIRAY)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-08-06","conditions":["Breast Neoplasms","Colorectal Neoplasms","Prostate Neoplasm","Endometrial Neoplasms","Neoplasm Metastasis"],"enrollment":421,"completionDate":"2035-04"},{"nctId":"NCT05700461","phase":"PHASE1","title":"Drug Screening Using Novel IMD in Renal Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Oliver Jonas","startDate":"2024-12-01","conditions":["Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Kidney Cancer"],"enrollment":20,"completionDate":"2029-08-31"},{"nctId":"NCT07340541","phase":"PHASE2","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02","conditions":["Breast Cancer","Metastatic Breast Cancer","Triple Negative Breast Cancer","Estrogen-receptor-positive Breast Cancer","Hormone Receptor Negative Breast Carcinoma"],"enrollment":700,"completionDate":"2031-06-02"},{"nctId":"NCT07174336","phase":"PHASE3","title":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-22","conditions":["Breast Neoplasms","Neoplasm Metastasis"],"enrollment":920,"completionDate":"2033-05"},{"nctId":"NCT05573126","phase":"PHASE1,PHASE2","title":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","status":"RECRUITING","sponsor":"Ellipses Pharma","startDate":"2023-01-11","conditions":["Hormone Receptor-positive Breast Cancer","Hormone Receptor Positive HER-2 Negative Breast Cancer","Metastatic Breast Cancer"],"enrollment":95,"completionDate":"2028-02"},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":["Lymphoma, Non-Hodgkin","Multiple Myeloma","Advanced Solid Tumors"],"enrollment":4200,"completionDate":"2028-12-31"},{"nctId":"NCT07209449","phase":"PHASE2","title":"A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-10-01","conditions":["Endometrial Cancer"],"enrollment":75,"completionDate":"2028-10-01"},{"nctId":"NCT07475923","phase":"","title":"Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-08-26","conditions":["Molecular Surveillance","Breast Cancer","ctDNA","MRD","Observational Study"],"enrollment":300,"completionDate":"2033-12-31"},{"nctId":"NCT03643510","phase":"PHASE2","title":"Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-08-21","conditions":["Adenocarcinoma of Endometrium"],"enrollment":28,"completionDate":"2026-03-12"},{"nctId":"NCT04802759","phase":"PHASE1,PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-22","conditions":["Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer"],"enrollment":316,"completionDate":"2029-05-30"},{"nctId":"NCT03424005","phase":"PHASE1,PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":["Metastatic Breast Cancer"],"enrollment":792,"completionDate":"2030-09-30"},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":["Breast Neoplasms","Breast Cancer","Breast Tumors","Angiosarcoma","TNBC - Triple-Negative Breast Cancer","HER2-positive Breast Cancer","HER2-negative Breast Cancer","Hormone Receptor Positive Tumor","Hormone Receptor Negative Tumor","Early-stage Breast Cancer","Locally Advanced Breast Cancer"],"enrollment":5000,"completionDate":"2031-12"},{"nctId":"NCT05940493","phase":"PHASE2","title":"Abemaciclib in Newly Diagnosed Meningioma Patients","status":"RECRUITING","sponsor":"Nader Sanai","startDate":"2025-03-24","conditions":["Meningioma"],"enrollment":72,"completionDate":"2030-09"},{"nctId":"NCT05440786","phase":"PHASE2","title":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-09-20","conditions":["Sarcoma, Ewing","Neoplasm Metastasis"],"enrollment":46,"completionDate":"2028-09"},{"nctId":"NCT04293393","phase":"PHASE2","title":"Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2020-10-02","conditions":["Early Breast Cancer"],"enrollment":200,"completionDate":"2033-02-28"},{"nctId":"NCT06380751","phase":"PHASE3","title":"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-01","conditions":["Advanced Breast Cancer"],"enrollment":500,"completionDate":"2030-10-18"},{"nctId":"NCT07100106","phase":"PHASE1,PHASE2","title":"A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2025-10-07","conditions":["Breast Cancer"],"enrollment":285,"completionDate":"2028-08-31"},{"nctId":"NCT04862663","phase":"PHASE3","title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-05-10","conditions":["Locally Advanced (Inoperable) or Metastatic Breast Cancer"],"enrollment":895,"completionDate":"2029-08-14"},{"nctId":"NCT05524584","phase":"PHASE2","title":"Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2022-08-31","conditions":["Breast Cancer","Metastatic Breast Cancer","Hormone Receptor-positive Breast Cancer","HER2-negative Breast Cancer"],"enrollment":20,"completionDate":"2031-12-31"},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":["Ovarian Cancer"],"enrollment":176,"completionDate":"2028-05-30"},{"nctId":"NCT06065748","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-12-11","conditions":["Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer"],"enrollment":1050,"completionDate":"2029-02-12"},{"nctId":"NCT04393285","phase":"PHASE2","title":"Abemaciclib and Letrozole to Treat Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gynecologic Oncology Group","startDate":"2020-10-10","conditions":["Endometrial Cancer"],"enrollment":53,"completionDate":"2026-12-31"},{"nctId":"NCT06650423","phase":"","title":"Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2025-01-05","conditions":["Early Breast Cancer","Hormone Receptor Positive Tumor","HER2-negative Breast Cancer"],"enrollment":319,"completionDate":"2027-03-01"},{"nctId":"NCT04391595","phase":"EARLY_PHASE1","title":"LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients","status":"COMPLETED","sponsor":"Nader Sanai","startDate":"2020-07-11","conditions":["Glioblastoma","GBM","Glioma"],"enrollment":42,"completionDate":"2025-09-03"},{"nctId":"NCT07428018","phase":"PHASE2","title":"Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib","status":"NOT_YET_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2026-04-30","conditions":["Breast Cancer","HER2 + Breast Cancer","HR Positive","Neoadjuvant Therapy"],"enrollment":150,"completionDate":"2029-04-30"},{"nctId":"NCT05999968","phase":"PHASE1","title":"Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-01-12","conditions":["Prostatic Neoplasms"],"enrollment":10,"completionDate":"2026-01-21"},{"nctId":"NCT05708235","phase":"PHASE2","title":"A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-04-01","conditions":["Breast Cancer"],"enrollment":976,"completionDate":"2028-06-30"},{"nctId":"NCT03531645","phase":"PHASE2","title":"Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-13","conditions":["Malignant Neoplasms of Female Genital Organs"],"enrollment":18,"completionDate":"2027-09-30"},{"nctId":"NCT03994796","phase":"PHASE2","title":"Genetic Testing in Guiding Treatment for Patients With Brain Metastases","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2019-10-17","conditions":["CDK Gene Mutation","Metastatic Malignant Neoplasm in the Brain","Metastatic Malignant Solid Neoplasm","NTRK Family Gene Mutation","PI3K Gene Mutation","ROS1 Gene Mutation","KRAS G12C Mutation"],"enrollment":186,"completionDate":"2028-06"},{"nctId":"NCT02523014","phase":"PHASE2","title":"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2015-09-28","conditions":["Intracranial Meningioma","Recurrent Meningioma","NF2 Gene Mutation"],"enrollment":124,"completionDate":"2028-01"},{"nctId":"NCT06830720","phase":"","title":"A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-20","conditions":["Breast Neoplasms"],"enrollment":3250,"completionDate":"2030-06-30"},{"nctId":"NCT04238819","phase":"PHASE1,PHASE2","title":"A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-11-09","conditions":["Relapsed Solid Tumor","Refractory Solid Tumor"],"enrollment":47,"completionDate":"2025-08-19"},{"nctId":"NCT06486883","phase":"PHASE2","title":"Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype","status":"RECRUITING","sponsor":"MedSIR","startDate":"2025-06-30","conditions":["Advanced Breast Cancer","Advanced Breast Carcinoma","Hormone Receptor Positive Breast Carcinoma"],"enrollment":200,"completionDate":"2028-01"},{"nctId":"NCT07441369","phase":"PHASE2","title":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Fudan University","startDate":"2026-03-01","conditions":["Liver Metastases From Colorectal Cancer (mCRC)"],"enrollment":16,"completionDate":"2027-02-28"},{"nctId":"NCT06760637","phase":"PHASE3","title":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-01-06","conditions":["Breast Cancer"],"enrollment":1020,"completionDate":"2037-12-29"},{"nctId":"NCT05617885","phase":"PHASE1","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praful Ravi, MB BCHir, MRCP","startDate":"2023-08-09","conditions":["Metastatic Prostate Cancer","Non-metastatic Prostate Cancer","Prostate Cancer"],"enrollment":9,"completionDate":"2026-06-01"},{"nctId":"NCT06179303","phase":"PHASE2","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-22","conditions":["Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Locally Advanced Unresectable HER2-Negative Breast Carcinoma","Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma","Metastatic HER2-Negative Breast Carcinoma","Metastatic Hormone Receptor-Positive Breast Carcinoma"],"enrollment":60,"completionDate":"2028-06-01"},{"nctId":"NCT07225790","phase":"","title":"Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2025-11-03","conditions":["Advanced Breast Cancer"],"enrollment":3883,"completionDate":"2026-01-31"},{"nctId":"NCT06188520","phase":"PHASE1,PHASE2","title":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-05","conditions":["ER+ HER2- Advanced Breast Cancer","High-grade Serous Ovarian Cancer (HGSOC)"],"enrollment":564,"completionDate":"2027-08-04"},{"nctId":"NCT04751929","phase":"PHASE2","title":"Abemaciclib With or Without Atezolizumab for mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-08-20","conditions":["Prostate Cancer","Metastatic Castration-resistant Prostate Cancer"],"enrollment":19,"completionDate":"2026-04-30"},{"nctId":"NCT03130439","phase":"PHASE2","title":"Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-05-26","conditions":["Breast Cancer"],"enrollment":27,"completionDate":"2022-01-30"},{"nctId":"NCT07410559","phase":"PHASE2","title":"Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-07-01","conditions":["Breast Cancer"],"enrollment":189,"completionDate":"2031-07-01"},{"nctId":"NCT06678269","phase":"PHASE1","title":"A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-11-15","conditions":["Metastatic Breast Cancer","Stage IV Breast Cancer","Breast Cancer","Breast Cancer Stage IV","Breast Cancer Metastatic","HER2-negative Breast Cancer","HER2 Negative Breast Carcinoma","Hormone-receptor-positive Breast Cancer"],"enrollment":28,"completionDate":"2028-11-30"},{"nctId":"NCT07407439","phase":"","title":"Real-world Studies of CDK4/6 Inhibitors","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-06-01","conditions":["Breast Cancer"],"enrollment":245,"completionDate":"2027-06-01"},{"nctId":"NCT07406594","phase":"NA","title":"Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of Vermont Medical Center","startDate":"2027-10","conditions":["Breast Cancer","HER-2 Positive Breast Cancer"],"enrollment":12,"completionDate":"2031-10"},{"nctId":"NCT06585969","phase":"PHASE3","title":"A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Danish Breast Cancer Cooperative Group","startDate":"2026-01-01","conditions":["Metastatic Breast Cancer","ER-positive Breast Cancer","Luminal B","Her2 Enriched","Basal Like"],"enrollment":0,"completionDate":"2026-01-01"},{"nctId":"NCT06366347","phase":"PHASE2","title":"ALPINE: Maintenance Letrozole/Abemaciclib","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-09-25","conditions":["Endometrial Cancer","Recurrent Endometrial Cancer","TP53"],"enrollment":32,"completionDate":"2029-03-01"},{"nctId":"NCT05548127","phase":"PHASE1,PHASE2","title":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-02-23","conditions":["Breast Cancer"],"enrollment":37,"completionDate":"2026-09-01"},{"nctId":"NCT04923542","phase":"PHASE1,PHASE2","title":"Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-11-30","conditions":["Brain Metastases","HR+ Metastatic Breast Cancer"],"enrollment":31,"completionDate":"2026-12"},{"nctId":"NCT02152631","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2014-10-03","conditions":["Non Small Cell Lung Cancer"],"enrollment":453,"completionDate":"2026-12"},{"nctId":"NCT02747004","phase":"PHASE2","title":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2016-09-14","conditions":["Metastatic Breast Cancer"],"enrollment":234,"completionDate":"2026-12"},{"nctId":"NCT02763566","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2016-12-05","conditions":["Breast Cancer"],"enrollment":463,"completionDate":"2028-03"},{"nctId":"NCT04921904","phase":"PHASE1,PHASE2","title":"Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor Research Institute","startDate":"2021-06-11","conditions":["Metastatic Esophageal Adenocarcinoma","Metastatic Gastroesophageal Junction Adenocarcinoma"],"enrollment":8,"completionDate":"2026-06"},{"nctId":"NCT05386108","phase":"PHASE1,PHASE2","title":"Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2022-08-31","conditions":["Breast Neoplasms","Brain Neoplasms","Neoplasms by Site","Neoplasms","Breast Diseases","Central Nervous System Neoplasms","Brain Diseases","Central Nervous System Diseases"],"enrollment":73,"completionDate":"2026-12"},{"nctId":"NCT02246621","phase":"PHASE3","title":"A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","isPivotal":true,"startDate":"2014-11-06","conditions":["Breast Cancer"],"enrollment":493,"completionDate":"2026-12"},{"nctId":"NCT06810544","phase":"PHASE1,PHASE2","title":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","status":"RECRUITING","sponsor":"Tango Therapeutics, Inc.","startDate":"2025-03-24","conditions":["Non Small Cell Lung Cancer","Glioma Glioblastoma Multiforme","Glioma, Malignant","Solid Tumor","Non-Small Cell Adenocarcinoma","Lung Cancer","Brain Tumor"],"enrollment":191,"completionDate":"2027-09-30"},{"nctId":"NCT04481113","phase":"PHASE1","title":"Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-06-07","conditions":["Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","HER2 Negative Breast Adenocarcinoma","Hormone Receptor Positive Breast Adenocarcinoma","Invasive Breast Carcinoma","Multifocal Breast Carcinoma","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Unilateral Breast Carcinoma"],"enrollment":8,"completionDate":"2025-06-20"},{"nctId":"NCT05305924","phase":"PHASE2","title":"Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2021-02-25","conditions":["ER-Positive Breast Cancer","HER2-negative Breast Cancer"],"enrollment":28,"completionDate":"2027-12-01"},{"nctId":"NCT03616587","phase":"PHASE1","title":"Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-10-11","conditions":["ER+ HER2- Advanced Breast Cancer"],"enrollment":396,"completionDate":"2027-06-24"},{"nctId":"NCT02779751","phase":"PHASE1","title":"A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2016-11-14","conditions":["Non Small Cell Lung Cancer","Breast Cancer"],"enrollment":100,"completionDate":"2026-12"},{"nctId":"NCT02057133","phase":"PHASE1","title":"A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2014-03-10","conditions":["Breast Neoplasms"],"enrollment":198,"completionDate":"2026-12"},{"nctId":"NCT05696626","phase":"PHASE3","title":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","status":"RECRUITING","sponsor":"Sermonix Pharmaceuticals Inc.","startDate":"2023-10-31","conditions":["Metastatic Breast Cancer"],"enrollment":500,"completionDate":"2028-04"},{"nctId":"NCT04941274","phase":"PHASE1,PHASE2","title":"Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-09-29","conditions":["Kaposi Sarcoma"],"enrollment":86,"completionDate":"2028-06-01"},{"nctId":"NCT05933395","phase":"PHASE2","title":"Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2024-09-23","conditions":["Advanced Breast Cancer"],"enrollment":135,"completionDate":"2031-10"},{"nctId":"NCT05169567","phase":"PHASE3","title":"Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-03-11","conditions":["Breast Neoplasm","Neoplasm Metastasis"],"enrollment":368,"completionDate":"2027-12"},{"nctId":"NCT04964934","phase":"PHASE3","title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-30","conditions":["ER-Positive HER2-Negative Breast Cancer"],"enrollment":315,"completionDate":"2027-11-26"},{"nctId":"NCT06001762","phase":"PHASE2","title":"TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-10-05","conditions":["Breast Cancer","Early-stage Breast Cancer","High Risk Breast Carcinoma"],"enrollment":90,"completionDate":"2027-01-01"},{"nctId":"NCT06835972","phase":"PHASE1,PHASE2","title":"A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-02-14","conditions":["Metastatic Renal Cell Carcinoma","Translocation Renal Cell Carcinoma"],"enrollment":43,"completionDate":"2027-02"},{"nctId":"NCT04584853","phase":"PHASE3","title":"PreOperative Endocrine Therapy for Individualised Care With Abemaciclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2020-12-23","conditions":["Breast Cancer Female"],"enrollment":123,"completionDate":"2030-10"},{"nctId":"NCT04169074","phase":"PHASE2","title":"Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)","status":"TERMINATED","sponsor":"University of Arizona","startDate":"2021-06-16","conditions":["HNSCC"],"enrollment":7,"completionDate":"2025-01-13"},{"nctId":"NCT03891784","phase":"PHASE2","title":"Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2019-10-31","conditions":["Advanced Digestive System Neuroendocrine Neoplasm","Digestive System Neuroendocrine Tumor","Foregut Neuroendocrine Tumor","Hindgut Neuroendocrine Tumor","Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm","Metastatic Digestive System Neuroendocrine Neoplasm","Midgut Neuroendocrine Tumor","Pancreatic Neuroendocrine Tumor","Refractory Digestive System Neuroendocrine Neoplasm"],"enrollment":20,"completionDate":"2026-07"},{"nctId":"NCT06169371","phase":"PHASE4","title":"Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2023-12-28","conditions":["Breast Cancer"],"enrollment":50,"completionDate":"2030-11"},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":["Breast Cancer","ER-positive Breast Cancer","HER2-negative Breast Cancer","Metastatic Breast Cancer"],"enrollment":24,"completionDate":"2029-07-31"},{"nctId":"NCT07002177","phase":"PHASE1,PHASE2","title":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","status":"RECRUITING","sponsor":"Forward Pharmaceuticals Co., Ltd.","startDate":"2025-06-01","conditions":["Metastatic Breast Cancer","Breast Cancer Stage I","Breast Cancer Stage II","Locally Advanced Breast Cancer (LABC)","ER+ Breast Cancer"],"enrollment":196,"completionDate":"2028-11-01"},{"nctId":"NCT05501704","phase":"PHASE2","title":"ETHAN - ET for Male BC","status":"RECRUITING","sponsor":"Jose Pablo Leone","startDate":"2023-10-11","conditions":["Male Breast Cancer","Hormone Receptor-positive Breast Cancer","Hormone Receptor Negative Breast Carcinoma"],"enrollment":60,"completionDate":"2036-04-01"},{"nctId":"NCT06630325","phase":"PHASE2","title":"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-24","conditions":["Advanced Breast Carcinoma","Advanced Malignant Solid Neoplasm","Advanced Ovarian Carcinoma","Advanced Pancreatic Carcinoma","Advanced Prostate Carcinoma","Advanced Sarcoma","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8"],"enrollment":30,"completionDate":"2033-06-30"},{"nctId":"NCT05563220","phase":"PHASE1,PHASE2","title":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2023-01-24","conditions":["Breast Cancer","Metastatic Breast Cancer"],"enrollment":435,"completionDate":"2028-12-28"},{"nctId":"NCT04750928","phase":"PHASE1,PHASE2","title":"Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-29","conditions":["Neurofibromatosis 1"],"enrollment":55,"completionDate":"2029-12-31"},{"nctId":"NCT07037199","phase":"PHASE2","title":"Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-18","conditions":["Advanced Breast Cancer"],"enrollment":45,"completionDate":"2030-06-30"},{"nctId":"NCT04616183","phase":"PHASE1,PHASE2","title":"LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-02","conditions":["Metastatic Colon Adenocarcinoma","Metastatic Colorectal Carcinoma","Metastatic Rectal Adenocarcinoma","Recurrent Colorectal Carcinoma","Stage III Colon Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage III Rectal Cancer AJCC v8","Stage IIIA Colon Cancer AJCC v8","Stage IIIA Colorectal Cancer AJCC v8","Stage IIIA Rectal Cancer AJCC v8","Stage IIIB Colon Cancer AJCC v8","Stage IIIB Colorectal Cancer AJCC v8","Stage IIIB Rectal Cancer AJCC v8","Stage IIIC Colon Cancer AJCC v8","Stage IIIC Colorectal Cancer AJCC v8","Stage IIIC Rectal Cancer AJCC v8","Stage IV Colon Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Stage IV Rectal Cancer AJCC v8","Stage IVA Colon Cancer AJCC v8","Stage IVA Colorectal Cancer AJCC v8","Stage IVA Rectal Cancer AJCC v8","Stage IVB Colon Cancer AJCC v8","Stage IVB Colorectal Cancer AJCC v8","Stage IVB Rectal Cancer AJCC v8","Stage IVC Colon Cancer AJCC v8","Stage IVC Colorectal Cancer AJCC v8","Stage IVC Rectal Cancer AJCC v8","Unresectable Colon Adenocarcinoma","Unresectable Colorectal Carcinoma","Unresectable Rectal Adenocarcinoma"],"enrollment":46,"completionDate":"2028-12-31"},{"nctId":"NCT07214532","phase":"NA","title":"Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Natera, Inc.","startDate":"2026-03","conditions":["Breast Neoplasms","Carcinoma, Ductal, Breast","Receptors, Estrogen (for ER-positive Requirement)"],"enrollment":725,"completionDate":"2037-12-30"},{"nctId":"NCT07243002","phase":"","title":"Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-12-15","conditions":["Breast Cancer"],"enrollment":3000,"completionDate":"2030-05-30"},{"nctId":"NCT07292207","phase":"PHASE2","title":"Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Nagoya City University","startDate":"2026-01-10","conditions":["ctDNA Monitoring","Breast Cancer"],"enrollment":30,"completionDate":"2031-08-31"},{"nctId":"NCT04603183","phase":"PHASE2","title":"ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL","status":"COMPLETED","sponsor":"MedSIR","startDate":"2021-06-02","conditions":["Breast Cancer Metastatic"],"enrollment":162,"completionDate":"2025-06-30"},{"nctId":"NCT06409390","phase":"PHASE2","title":"Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-08-14","conditions":["Metastatic Breast Cancer"],"enrollment":15,"completionDate":"2027-04"},{"nctId":"NCT07264998","phase":"","title":"Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea","status":"NOT_YET_RECRUITING","sponsor":"Hubei Cancer Hospital","startDate":"2025-12","conditions":["Breast Neoplasms","Hormone Receptor-Positive Breast Cancer","Abemaciclib","Abemaciclib-related Diarrhea","Drug-induced Diarrhea","Gastrointestinal Microbiome (Focus)","Microbiome"],"enrollment":60,"completionDate":"2026-07"},{"nctId":"NCT04010357","phase":"PHASE2","title":"Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2020-01-13","conditions":["Small-cell Lung Cancer","Large Cell Neuroendocrine Carcinoma of the Lung","Extrapulmonary Small Cell Carcinoma"],"enrollment":14,"completionDate":"2025-12"},{"nctId":"NCT06495164","phase":"","title":"A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-06-24","conditions":["Breast Cancer","Malignant Neoplasm of Breast"],"enrollment":1,"completionDate":"2026-12-30"}],"_emaApprovals":[{"date":"2018-09-26","status":"Authorised","company":"Eli Lilly Nederland B.V."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT03155997","NCT02246621","NCT02107703","NCT02102490"],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"Verzenio"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"262389","NDDF":"017349","UNII":"60UAB198HK","VANDF":"4036932","INN_ID":"10036","RXNORM":"1946825","UMLSCUI":"C3852841","chemblId":"CHEMBL3301610","ChEMBL_ID":"CHEMBL3301610","KEGG_DRUG":"D10688","DRUGBANK_ID":"DB12001","PDB_CHEM_ID":" 6ZV","PUBCHEM_CID":"46220502","SNOMEDCT_US":"761851004","IUPHAR_LIGAND_ID":"7382","MESH_SUPPLEMENTAL_RECORD_UI":"C000590451"},"formularyStatus":[],"originalProduct":{"form":"TABLET","route":"ORAL","company":"Eli Lilly and Company","brandName":"Verzenio","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2017-","companyName":"Eli Lilly","relationship":"Original Developer"},{"period":"2018","companyName":"Eli Lilly Japan KK","relationship":"PMDA Licensee"},{"period":"2018","companyName":"Eli Lilly","relationship":"EMA Licensee"}],"pharmacokinetics":{"tmax":"8.0 hours (median, range 4.1-24.0 hours)","halfLife":"18.3 hours (mean, 72% CV)","clearance":"26.0 L/h (geometric mean hepatic clearance, 51% CV)","excretion":"Approximately 81% recovered in feces and 3% in urine after single 150 mg oral dose; majority of fecal elimination is metabolites","metabolism":"Hepatic metabolism via CYP3A4 primarily; major pathway is N-desethylabemaciclib (M2); additional metabolites include M20, M18, and M1; M2, M18, M20 are equipotent to abemaciclib","proteinBinding":"96.3% (1.1 SD) for abemaciclib; 93.4% (1.3 SD) for M2; 96.8% (0.8 SD) for M18; 97.8% (0.6 SD) for M20","bioavailability":"45% (19% CV) after single oral 200 mg dose","volumeOfDistribution":"690.3 L (geometric mean, 49% CV)"},"publicationCount":1348,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-08 13:57:13.184729+00","atcClassification":{"source":"DrugCentral","atcCode":"L01EF03","allCodes":["L01EF03"]},"biosimilarFilings":[],"originalDeveloper":"Eli Lilly And Co","recentPublications":[],"companionDiagnostics":[{"biomarker":"Hormone receptor (HR)-positive","requirement":"required","diagnosticId":"cdx-0","diagnosticName":"FDA-approved test"},{"biomarker":"Human epidermal growth factor receptor 2 (HER2)-negative","requirement":"required","diagnosticId":"cdx-1","diagnosticName":"FDA-approved test"}],"genericManufacturers":0,"_genericFilersChecked":true,"structuredTrialResults":[{"hr":"0.00","nctId":"NCT03280563","phase":"PHASE1, PHASE2","pValue":"","ciLower":"-21.14","ciUpper":"21.14","endpoint":"Stage 1: Percentage of Participants With Objective Response","enrollment":144},{"hr":"0.0","nctId":"NCT03130439","phase":"PHASE2","pValue":"","ciLower":"0.000","ciUpper":"0.247","endpoint":"Objective Response Rate","enrollment":27}],"genericManufacturerList":[],"status":"approved","companyName":"Eli Lilly And Co","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"2017","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-03-03T00:00:00.000Z","mah":"ELI LILLY AND CO","brand_name_local":null,"application_number":"NDA208716"},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":74,"withResults":10},"validation":{"fieldsValidated":9,"lastValidatedAt":"2026-04-20T08:33:52.036709+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}